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ABSTRACT
Antibodies targeting various tumor-associated antigens have been developed
successfully to treat cancer. In this Thesis, novel antibodies and antibody-conjugate
against two tumor antigens, AF-20 antigen and human aspartyl (asparaginyl) 3-
hydroxylase (HAAH), were developed. Previously, these two tumor antigens have been
shown to be present on a variety of tumor cells, while they have minimal expression on
normal tissues, rendering them excellent targets for antibody therapy.
For the AF-20 work, the variable region (V) gene of a previously isolated mouse
monoclonal antibody (mAb) AF-20 was cloned from hybridoma mRNA and used to
construct an AF-20 single-chain Fv (scFv). The AF-20 scFv was shown to bind
specifically to the same epitope as mAb AF-20 with a binding affinity of 4nM. The AF-
20 scFv was also internalized into tumor cells in a manner identical to that of the original
mAb AF-20. The scFv was later employed for cellular internalization of virus-sized
fluorescent quantum dots. In addition, to demonstrate the versatility of this antibody, an
immunotoxin composed of AF-20 scFv fused to the highly cytotoxic recombinant toxin
gelonin was constructed, and its in-vitro efficacy against three different tumor cell lines
were evaluated. The IC50 of the AF-20 scFv-gelonin fusion was consistently one to two
logs lower than the IC50 of free gelonin on FOCUS (liver), L3.6pl (pancreas) and PC3
(prostate) cells, further demonstrating the capability of the AF-20 scFv as a targeting
module. Therefore, this AF-20 scFv is a potential internalization vector for toxins,
enzymes, radionuclides and virus for targeted therapy of AF-20-antigen expressing tumor
cells.
For the HAAH study, twelve novel human scFv against HAAH were isolated
from a human non-immune scFv library displayed on the surface of yeast. Five of the
twelve scFv were reformatted as human IgG 1. One of the reformatted IgG, 6-22, showed
significant binding to recombinant HAAH protein in ELISA, tumor cell lines, and tumor
tissues. 6-22 IgG was also shown to target the catalytic domain of HAAH, and its
apparent dissociation constant was determined to be 1.OnM. 6-22 IgG alone does not
exhibit significant cytotoxicity toward the tumor cells. However, 6-22 IgG internalizes
into tumor cells and can therefore be employed to deliver cytotoxic moieties into tumor
cells. A goat anti-human IgG-saporin conjugate was delivered into tumor cells by 6-22
IgG and hence elicited cytotoxicity toward the tumor cells in vitro. Meanwhile, the
monovalent affinity of 6-22 scFv was too low for therapeutic or diagnostic application, so
6-22 scFv was affinity matured using directed evolution and yeast surface display. After
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two rounds of mutagenesis, a mutant, C4-18, with an affinity of 0.6nM was isolated.
Overall, these human ax-HAAH scFv and IgG can potentially be used in the diagnosis and
therapeutic treatment of HAAH-expressing tumor cells.
Thesis Supervisor: K. Dane Wittrup
Title: J.R. Mares Professor of Chemical Engineering and Bioengineering
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Chapter 1: Introduction and Background
1.1 Antibody Structure and Function
Antibody is involved in the humoral branch of the adaptive immunity. Antibodies,
produced by B cells, recognize pathogens or foreign molecules through specific binding
to the antigen. This specific interaction can neutralize the antigen or trigger effector
functions of the immune system to eliminate the antigen. Examples of the effector
functions are opsonization, activation of complement and antibody-dependent cell-
mediated cytotoxicity (ADCC).
Antibody consists of two identical light (L) chains and two identical heavy (H)
chains, as shown in Figure 1.1. The molecular weight of the light and heavy chain are
about 25 and 50OkDa respectively. Each light chain is bound to a heavy chain by a
disulfide bond and a combination of noncovalent interactions such as salt bridges,
hydrogen bonds and hydrophobic interaction. The amino-terminal regions of light and
heavy chains, which vary greatly among antibodies with different specificities, are called
variable (V) regions, VL for light chain and VH for heavy chain. The regions of relatively
constant sequences beyond the variable regions are called constant (C) regions, CL for
light chain and CH for heavy chain. Within the V regions, sequence variability is
concentrated in several hypervariable regions. These hypervariable regions, which
constitute the antigen-binding site of an antibody, are called complementarity-
determining regions (CDRs). The remaining domains of VL and VH, which exhibit far
less variation, are called the framework regions (FW).
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Figure 1.1 Schematics of Antibody Structure. (A) Antibody consists of two identical
light (red) and heavy (blue & yellow) chains. The amino-terminal regions of the light and
heavy chain, which are responsible for antigen binding, are called VH and VL. The Fc
region is involved in activating the effector function of immune system. The IgG picture
is adapted from www.antibodyresource.com intactab.htnil. (B) Antibody mediates
specific interaction with its antigen through the CDRs of the V.1 (blue and green) and VL
(red and yellow). The CDRs of VH and VL are shown in green and yellow respectively,
whereas the framework regions are shown in blue and red colors respectively for VaH and
VL.
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1.2 Antibody Engineering
Protein engineering has been employed extensively to modify the functions and
properties of antibodies (Hudson and Souriau, 2001). Examples of protein engineering
include reducing the size of an antibody from IgG format to single-chain Fv (scFv),
modifying the valency of an antibody, changing the affinity of Fc receptors, and more
frequently, improving the affinity and stability of an antibody. To date, given the
inconsistent results from rational protein design, directed evolution is still the most
effective method available for exploration and engineering of antibodies. Directed
evolution involves displaying a diverse array of antibody mutants on a genetic package
(Shusta, et al., 1999), and then selecting favorable mutants from the pool. Such packages,
which link the phenotype to its genotype, include ribosome (Hanes, et al., 1998; He and
Taussig, 1997; Mattheakis, et al., 1994), bacteriophage (Griffiths and Duncan, 1998;
McCafferty, et al., 1990; Smith, 1985), bacteria (Francisco, et al., 1992; Georgiou, et al.,
1997)and yeast (Boder and Wittrup, 1997; Boder and Wittrup, 2000).
1.2.1 Yeast Surface Display
Yeast surface display was previously developed in our lab for directed evolution
of protein. One of the advantages of using yeast for displaying protein is that as a
eukaryote, yeast contains similar protein-processing machinery to a mammalian cell.
Thus yeast is more likely than prokaryotes to correctly express and display mammalian
surface or secreted proteins, in this case antibodies. Yeast surface display involves
displaying the antibody of interest through fusion with a two-unit cell wall glycoprotein
called a-agglutinin, whose original function is to mediate cell-cell adhesion between a-
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Figure 1.2 Schematic of Yeast Surface Display. The antibody of interest (scFv) is
displayed on the yeast surface through fusion to Agal-Aga2 protein. Two epitopes tags,
HA and c-myc, are fused to the N-terminus and C-terminus of the antibody respectively.
The displayed antibody is able to bind ligands on the yeast surface, and the presence of
epitope tags can be detected using commercially available antibodies.
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type and -type haploid cells (Boder and Wittrup, 1997) (Figure 1.2). A-agglutinin
consists of two distinct domains, Agalp and Aga2p, connected by two disulfide bonds.
Agalp subunit anchors the assembly to the cell wall via a 3-glucan covalent linkage. The
antibody is fused to the C-terminus of Aga2p, where the native a-agglutinin binding
activity localizes. The antibody in the display construct is flanked by two epitope tags,
with hemagglutinin (HA) and c-myc on the N- and C-terminus of the antibody
respectively. Expression of the full-length antibody on the cell surface can be simply
confirmed by detecting the presence of c-myc tag on the cell surface using commercially
available antibodies. Additionally, due to the intrinsic quality control of the endoplasmic
reticulum (ER), the presence of c-myc tag on the cell surface strongly implies that the
surface displayed antibody is folded properly (Hammond and Helenius, 1995).
The number of displayed antibodies is on the order of 104 copies per cell. The
displayed antibody is able to bind ligands on the yeast surface. Specifically, surface-
displayed antibodies are incubated with soluble fluorophore-conjugated ligands. The
presence of fluorescence on the yeast cells, which indicates the binding of ligands, is
detected using a flow cytometer. The fluorescence from surface-displayed antibody
binding can be normalized with the simultaneous labeling of the epitope tags (HA or c-
myc), preventing any expression bias on the antibody binding fluorescence level.
Previously, yeast displaying anti-FITC scFv has been shown to bind simultaneously two
macromolecules, a 200kDa-size FITC-dextran and a 150kDa-size mouse antibody 9e10
(anti-c-myc IgG) (Boder and Wittrup, 1997). This demonstrates that the surface-
displayed antibodies are readily accessible to their antigens and there is minimal steric
hindrance from any cell wall components on the binding of the displayed antibody. In
12
addition, the dissociation constant of the antibody-antigen interaction can be measured
directly on the yeast surface by labeling the antibody-displaying yeast with different
concentrations of the antigen, eliminating the need for soluble antibody expression. The
dissociation constants measured from yeast surface were shown to be highly similar to
the ones measured using soluble antibodies (Boder, et al., 2000).
1.2.2 Mutagenesis and Library Screening
Antibody engineering using yeast surface display involves mutagenizing the
antibody gene, displaying the library of mutant antibodies on the yeast surface and
subsequently screening for the desired mutants. Multiple methods have been used to
mutagenize an antibody gene: random mutagenesis (Boder, et al., 2000; Daugherty, et
al., 2000a; Graff, et al., 2004; Leung, 1989), hot-spot site directed mutagenesis
(Chowdhury and Pastan, 1999; Goyenechea and Milstein, 1996), targeted mutagenesis of
complementary determined region (CDR) residues (Schier, et al., 1996b; Wu, et al.,
1998; Yang, et al., 1995), DNA shuffling (Crameri, et al., 1996; Graff, et al., 2004; van
den Beucken, et al., 2001; Zhao, et al., 1998), CDR shuffling (Ellmark, et al., 2002;
Jirholt, et al., 1998; Marks, et al., 1992; Schier, et al., 1996a), and chain shuffling (Marks,
et al., 1992; Schier, et al., 1996a).
Random mutagenesis introduces amino acid changes throughout the entire
antibody sequence. One of the most frequently used random mutagenesis techniques is
error-prone PCR. In error-prone PCR, mutations are intentionally introduced during PCR
through the use of error-prone DNA polymerases and reaction conditions (Cadwell and
Joyce, 1992; Leung, 1989). Taq DNA polymerase, which lacks proofreading ability, is
commonly employed in error-prone PCR and introduces on average 10-4 error per base
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pair. To attain practical mutation frequencies, the error rate of Taq DNA polymerase is
further increased by altering PCR reaction buffers, such as by using unbalanced dNTP
concentrations (Cadwell and Joyce, 1992) during the reaction, by addition of manganese
(Leung, 1989), or by addition of nucleoside analogues (Zaccolo and Gherardi, 1999;
Zaccolo, et al., 1996). The desired range of mutation frequencies is usually achieved by
controlling the amount of the different reagents added and the number of PCR cycles. For
example, in the case of random mutagenesis using nucleoside analogues, concentration of
the nucleoside analogues and number of PCR cycles can both be used to control mutation
rate. Typical. mutation frequency for an antibody in random mutagenesis is from 0.5% to
3%.
On the other hand, other mutagenesis techniques, which target particular regions
of an antibody, have also been used to improve the affinity of an antibody. One of the
most commonly targeted regions is the CDRs of an antibody, as the CDRs are
responsible for the direct interaction with the antigen. Mutagenesis targeting antibody
CDRs would minimize the structural change in the antibody framework, as mutations are
being concentrated in the CDRs only. Minimal framework residue alteration is particular
important in the engineering of human antibodies, since changes in the framework
residues may affect the immunogenicity of an antibody.
Overall, different mutagenesis methods have different advantages and each one
achieves a different objective. Considerations such as ease and rate of mutagenesis,
extent of affinity improvement per round of mutagenesis, and immunogenicity of the
mutants, should be taken into account when choosing an appropriate mutagenesis
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method. However, these mutagenesis methods can also be applied in a sequential manner
to affinity mature an antibody over several rounds of mutagenesis.
After mutagenesis, improved mutants are screened using yeast surface display.
These mutant genes, along with the restriction enzyme-digested display plasmid
backbone, are co-transformed into yeast. Through homologous recombination in yeast,
full-length plasmids containing the mutant genes are created (Gunyuzlu, et al., 2001). A
typical number of transformants in a random mutagenesis library is approximately 107
per 10 jgg of mutant DNA. In general, if the antigen is available in soluble form,
fluorescence-activated cell sorting (FACS) can be employed to isolate the improved
mutants from the library. The mutant library is first labeled at the desired equilibrium or
kinetic binding conditions to provide maximum fluorescence differentiation between the
improved mutants and the wild-type scFvs (Boder and Wittrup, 1998). Then FACS is
used to isolate the improved mutants, which have higher fluorescence intensity. Optimal
equilibrium and kinetic binding conditions for the cell labeling have been calculated from
mathematical models (Boder and Wittrup, 1998). Screening using optimal labeling and
FACS allow for separation of mutants based on a specified quantitative improvement in
affinity. With optimal labeling, FACS has been shown to be capable of discriminating
with precision and reproducibility minimally-improved mutant over wild type yeast
(VanAntwerp and Wittrup, 2000). Current FACS instrumentation is capable of sorting up
to 108 cells per hour. With a library of 107 yeast transformants, a ten-fold over-sampling
of the library requires about I hour to sort. Typically, four to five rounds of screening
will be performed to enrich the library to a panel of improved clones. If library size is in
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excess of 108, magnetic beads can be used to enrich the populations, so that the library
size can be manageable by FACS (Siegel, et al., 2004).
Previously, yeast surface display has been used to affinity mature an anti-
fluorescein antibody from InM to 50fM in 4 rounds of mutagenesis and screening
(Boder, et al., 2000). In addition, the dissociation rate of an anti-carcinoembryonic
antigen (CEA) antibody has also been improved over 1000 fold (from a half-life of 10
minutes to 4-7 days at 370C) after 2 rounds of mutagenesis and screening using yeast
surface display (Graff, et al., 2004). Therefore, yeast surface display has been shown to
be a robust screening method, and is used in this study to isolate novel binder and to
engineer antibodies.
1.3 Antibody Therapeutics for Cancer Therapy
1.3.1 Tumor Antigens
Malignant transformation of the cell is usually associated with alteration in the
surface antigenic composition. Tumor antigens can result from genetic mutation in tumor
cells that generate altered cellular proteins; these kinds of antigens are unique to the
tumor cells. These genetic mutations can be induced chemically, physically or virally (i.e.
Epstein-Barr virus and Human Papilloma virus). In addition, tumor cell surface antigens
can also be aberrantly glycosylated (Tag-72 and Mucins), rendering them different from
those on the normal cells (Urban and Schreiber, 1992). However, there are also tumor
antigens that are not unique to the cancer cells; these tumor antigens are normally present
on healthy cells. When the cells become malignant, the expression profile or level of
these antigens change dramatically. One example of aberrant expression profiles is
carcinoembryonic antigen (CEA). Tumor cells express CEA over the entire surface of the
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cells, while in normal cells, CEA is only present on the apical surface of the cells
(Hammarstrom, 1999). Meanwhile, tumor antigens can also be over-expressed when cells
become cancerous. Examples are CD20 overexpression in non-Hodgkin lymphoma and
CD44 overexpression in lung cancer. When these tumor-associated antigens are
expressed at a level (higher density) that can significantly distinguish their malignant
phenotypes from the normal healthy phenotypes, this makes them (antigens) excellent
targets for antibody-targeted therapy.
1.3.2 Mechanism of Tumor Killing
Antibody can block tumor growth or mediate the killing of tumor cell by several
different mechanisms (Houghton and Scheinberg, 2000). First, antibody can bind to the
growth factor receptors or other signaling molecules on the cancer cells, leading to
apoptosis or inhibition of the cell growth (Groner, et al., 2004). Examples are
Bevacizumab, which binds vascular endothelial growth factor (VEGF), and Cetuximab,
which block the binding of EGF or TGF-a against EGFR. Another way to mediate killing
is to recruit the natural immune system to kill tumor cells. Antibody bound to the cancer
antigen can activate the complement components, leading to opsonization of cancer cells
by complement receptors-expressing phagocytic cells, direct lysis of tumor cells and
inflammation with recruitment of inflammatory cells. In addition, the bound antibody
can bind to the activating Fc receptors on the effector cells like macrophages and NK
cells, leading to antibody-dependent cellular cytotoxicity (ADCC) or release of cytokines.
Examples are Rituxan® in the treatment of non-Hodgkin's lymphoma and Herceptin in
the treatment of metastatic breast cancer. Besides using naked antibody to cure cancer,
antibodies or antibody fragments can be conjugated with different cytotoxic moieties to
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kill the tumor cells. These cytotoxic moieties include a variety of entities, ranging from
radionuclide molecules to a virus carrying therapeutic genes or a liposome carrying loads
of drugs, toxins, or enzymes (Trail and Bianchi, 1999). For example, antibody BR96-
doxorubicin conjugate was used to target LeY-related tumor-associated antigen expressed
on most human carcinoma (Trail, et al., 1993). Antibody-directed drug delivery can
improve the therapeutic efficacy of cytotoxic moieties by targeting tumor cells
specifically while reducing the potential systemic toxicities of the drugs. However, the
success of a targeted cell-killing function is predicated on the existence of tumor-
associated antigens.
1.3.3 Current Antibody Therapeutics
Antibodies targeting various tumor-associated antigens have been developed
successfully to treat cancer. Currently, there are eight monoclonal antibodies approved by
the Food and Drug Administration (FDA) for cancer therapy. Table .1 summarizes these
FDA-approved antibodies and their targets. These approved antibodies can be divided
into two types, naked and conjugated. Naked antibodies are those without any moiety
attached to it; while conjugated antibodies have either toxin, radioactive material or
cytotoxic drug attached to them. Most of the approved antibodies, except Bexxar, are
either chimaeric or humanized, minimizing the neutralization effect of HAMA (human
anti-murine antibody). In addition to these approved antibodies, there are hundreds of
clinical trials worldwide involving the use of antibodies to treat cancer
(www.clinicaltrials.gov). In general, antibody has been proven to be a successful
molecule for targeted cancer therapy.
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Table 1.1 FDA Approved Antibodies for Cancer Therapy
Antibody Type Target Condition Approved
Rituxan Chimaeric CD20 Non-Hodgkin's Nov, 1997Lymphoma
Herceptin Humanized HER2 Metastatic Breast Caner Sept, 1998
Mylotarg Humanized CD33 Acute Myelogenous May 2000
(Toxin: calicheamicin) Leukemia
Campath Humanized CD52 Chronic Lymphocytic May, 2001Leukemia
Zevalin Chimaeric Non-Hodgkin'sli  CD20 Feb, 2002(In-l I or Y-90 linked) Lymphoma
Bexxar Murine Non-Hodgkin's Jun,2003
(I-131 linked) CD- - Lymphoma
Erbitux Chimaeric EGFR Metastatic Colorectal Feb, 2004Cancer
Metastatic ColorectalAvastin Humanized VEGF Metastatic Colorectal Feb, 2004Cancer
1.4 Thesis Overview
In this work, antibodies and antibody-conjugates against two tumor antigens, AF-
20 antigen and human aspartyl (asparaginyl) 3-hydroxylase (HAAH), were developed.
These two antigens have been previously shown to be present on a variety of tumor cells;
while they have minimal expression on normal tissues, rendering them good targets for
antibody therapy.
Chapter 2 of this thesis describes the development of an antibody fragment and an
antibody toxin conjugate against AF-20 antigen. Previously, a mouse monoclonal
antibody (AF-20) was raised against this antigen; however, the gene of this antibody was
not available. In this work, the gene of AF-20 antibody was cloned and used to construct
an antibody fragment (scFv). The antibody fragment was characterized and shown to
function similarly as its parental IgG counterpart. Antibody-toxin conjugate was also
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constructed to illustrate that the antibody fragment can be a targeting domain for
immunotoxin to treat a variety of cancers.
Chapter 3 of the thesis gives details about the isolation and engineering of novel
human antibodies against HAAH using yeast surface display. Novel human antibody
fragments (scFv) were isolated against HAAH, and then converted into IgG formats.
These human IgGs were shown to bind specifically to the tumor cells, illustrating the
potential use of them in cancer diagnosis and therapy. One of the antibodies was also
affinity matured using directed evolution and yeast surface display.
Chapter 4 focuses on the development of a quantitative screening tool, magnetic
bead capture, for cell-based polypeptide library screening. Magnetic bead capture was
used as an alternative tool to the flow cytometric sorting for screening of favorable
mutants from a library. Results showed that magnetic bead capture probability of labeled
cells correlated closely with the surface ligand density, and magnetic beads capture was
capable of quantitatively screening for both novel binders from an excess of non-binders
and high-affinity binders from an excess of low-affinity binders.
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Chapter 2: Characterization of a Single-chain Fv for Delivery
of Cytotoxic Moieties to Hepatocellular Carcinoma Cells
2.1 Introduction
Antibodies have been employed extensively in recent years for the treatment of
various diseases, in particular cancer (Carter, 2001; Gura, 2002). Tumor cell killing can
be achieved by blocking the biological function of the antigen, through recruitment of
immune effector functions or through delivery of attached toxins or radionuclides.
Previously, monoclonal antibody (Mab) AF-20 was obtained by immunizing BALB/c
mice with the FOCUS cell line, isolated from a poorly differentiated hepatitis B virus
positive hepatocellular carcinoma (HCC) (He, et al., 1984; Wilson, et al., 1988). The
antigen to which AF-20 IgG binds has been partially characterized (Moradpour, et al.,
1995). The antigen is a 180kDa homodimeric glycoprotein found on a variety of cancers
including liver, pancreatic, prostate, colon and breast tumor cell lines, while it has
minimal expression on normal tissues. However, full identification of this antigen is still
in progress.
AF-20 antigen expression is particularly prevalent in hepatocellular carcinoma,
where it is expressed on 75 of 75 primary HCC tumors and on distant metastases. HCC
comprises about 90% of the primary liver cancer in the United States, and the incidence
for this tumor type has increased recently (El-Serag, et al., 2003; El-Serag and Mason,
1999). Common cancer therapies like chemotherapy and radiotherapy are relatively
ineffective in treating HCC and prognosis remains poor despite a variety of other
treatment options including surgical resection, chemoembolization, and percutaneous
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injection of ethanol. Immunotherapy using AF-20 IgG would present an attractive
alternative option for the treatment of HCC.
Previously, an iodinated form of AF-20 IgG showed excellent localization toward
target tumor cells in vivo, and the highly specific and sensitive interaction rendered this
antigen to be a potential target for immunotherapy (Takahashi, et al., 1989). One
interesting property of this antigen is that once AF-20 IgG is bound, the complex is
rapidly internalized at 370C (Moradpour, et al., 1995). Utilizing this internalization
property of the antigen, AF-20 IgG has been conjugated chemically to different moieties
to specifically deliver both detection and therapeutic DNA to tumor cells. Examples of
the moieties conjugated include liposomes (Moradpour, et al., 1995), DNA-binding
cholesteryl-spermine (Mohr, et al., 1999) and adenovirus (Mohr, et al., 2000; Yoon, et al.,
2000). Overall, AF-20 IgG has been proven to be an effective antibody for targeting
tumor cells in mice. However for targeting solid tumors, whole intact IgG has poor tumor
penetration properties (Jain and Baxter, 1988). One possible way to improve the tumor
targeting properties of AF-20 IgG is to reduce its size. Fragments of antibodies like
single-chain Fv (scFv) have better penetration abilities and faster whole body clearances
than the intact IgG (Adams, et al., 1993; Yokota, et al., 1992; Yokota, et al., 1993),
exhibiting potentially better pharmacokinetics for tumor targeting. Genetic fusion of AF-
20 antibody fragments with protein toxins or enzymes or conjugates with virus particles
or toxins are also of interest for targeted therapy of cancer.
In this study, we have cloned the V gene of AF-20 IgG and use it to construct a
scFv. The scFv was displayed on the yeast surface and secreted as soluble form from
yeast. The soluble AF-20 scFv was shown to bind to the same epitope as AF-20 IgG with
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a binding affinity of 4nM. The AF-20 scFv also retained the internalization ability of the
AF-20 IgG, and was shown to facilitate the internalization of virus-sized particles,
Quantum Dots, into the tumor cells. These studies demonstrate the potential of using the
AF20 scFv to target virus particles or liposome vehicles to HCC and other tumor cells
expressing AF-20 antigen. Also, the potential of immunotherapy using AF-20 scFv as the
targeting domain of an immunotoxin was explored. The toxin used in this study was the
recombinant plant toxin gelonin (Falasca, et al., 1982). Our results show that AF-20
scFv-gelonin fusions consistently gave higher cytotoxicities than native gelonin on
different tumor cell lines. Overall, this study demonstrates the promise of using
engineered antibody fragments derived from Mab AF-20 for targeted therapy of HCC and
other cancers.
2.2 Materials and Methods
2.2.1 Cloning of the AF-20 V Genes
Hybridoma cells expressing AF-20 IgG were cultured in media consisting of
Dulbecco's modified eagle media (Sigma, St Louis, MO), 20% fetal calf serum (Hyclone,
Logan, UT), 2% glutamine, l00U/ml penicillin and 0.1mg/ml streptomycin (Sigma).
Cells were grown in T-flasks at 370C in a 5% CO2 atmosphere. About 108 cells were
grown up for RNA isolation, and total RNA was isolated using guanidinium thiocyanate
precipitation as described in the Ig Prime Kit protocol (Novagen, Madison, WI). First
strand cDNA synthesis was carried out as described in the Ig Prime Kit protocol. The
PCR amplification reactions were then setup respectively for the heavy and light chains
using the mouse IgG and kappa light chain primer sets provided by the kit. PCR products
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were run on a 1% agarose gel and stained. DNA bands in the region of 400 to 500 bp
were excised, purified and ligated into pSTBluel using the Perfectly Blunt Cloning Kit
(Novagen). The ligated products were transformed into Nova Blue E. coli cells
(Novagen), and the resulting plasmids were isolated from the E. coli and sequenced to
determine the identity of the AF-20 heavy and light chain variable regions.
2.2.2 Construction of the AF-20 scFv
The scFv was constructed in the configuration of VH-Linker-VL using the splicing
by overlap extension (SOE) PCR method (Horton, et al., 1989; Krebber, et al., 1997). A
20-amino acid linker with four repeats of (Gly)4-Ser was used. The VH chains were
amplified using VH 5'primer: gatcgatcgagctagc-caggtccaactgcagcagtc, and VH 3'primer:
ccactctcacagtctcctcaggtggtgg-tggttctggtggtggtggttctggcggcggcggctcc. The VL chains
were amplified using VL 5'primer: ggcggcggcggctccggaggaggaggatcggacatcttgctgactcag
and VL 3'primer: gggacaaagttggaaataaaaaatggctgatgctggtggatcccatcatcatcatcatcattgataactc
gaggctcgatcgatc. The VL 3'primer incorporated an arginine to asparagine mutation at a
lysine-arginine site near the c-terminus in order to remove a potential Kex2 cleavage site.
PCR reactions were carried out on a Perkin Elmer DNA Thermal Cycler 480 in a 100 gL
volume using 100 ng of template, I uM of primers, 0.2 mM of dNTP, 5 U Pfu
Polymerase (Invitrogen, Carlsbad, CA). The cycling conditions used were I cycle of
96C for 2 minute followed by 30 cycles of 96°C for I minute, 53°C for I minute and
72°C for 2 minutes, and finally 1 cycle of 72°C for 10 minutes. The VH and VL PCR
fragments were separately gel-purified. The SOE reaction contained 400RM of each
dNTP, 2g each of the VH and VL PCR products and 5U of Pfil Polymerase in 100 L
volume. The reaction was run for 5 cycles with no primers at cycling conditions of 96 °C
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for 1 minute, 53C for 1 minute, 72°C for 2 minutes and then followed by 1 cycle of 72°C
for 10 minutes. Outside primers (VH 5'primer and VL 3'primer) were then added to the
reaction for a further 15 cycles. The PCR product was gel purified, restriction-digested
with NheI and Xhol, and ligated into the corresponding sites in the pRS based secretion
vector. The ligated product was then transformed into XL1-Blue E. coli cells (Stratagene,
La Jolla, CA) for amplification and sequencing.
2.2.3 Soluble Expression of AF-20 scFv
The AF-20 scFv secretion plasmid along with a plasmid contain a Trp marker
were co-transformed into yeast strain YVHIO using lithium acetate method (Gietz and
Schiestl, 1991). The pRS based yeast secretion vector and the yeast strain have been
previously described (Parekh, et al., 1995; Robinson, et al., 1994). Yeast culturing and
induction of scFv secretion were performed as previously described (Shusta, et al., 1998).
The yeast supernatant containing soluble scFv was concentrated using stirred cell protein
concentrator series 8000 from Millipore (Billerica, MA). The concentrated protein
solution was then purified using Nickel-NTA resin according to the manufacturing
protocol from Qiagen (Valencia, CA). Nickel-column-purified AF-20 scFv was dialyzed
in PBS (pH 7.4) for later experiments.
2.2.4 Coomassie Gel Analysis and Western Blot
Various amount of protein samples were resolved by SDS-PAGE gel
electrophoresis using a 4% stacking and 12.5% resolving gel. For Coomassie analysis,
the gel was stained with Coomassie staining solution (0.4g/L stain, 7% acetic acid, 35%
methanol) for I hour and destained overnight in destain buffer (7% acetic acid, 35%
methanol). Images of the bands were taken with Fluor-S imager (Bio-Rad, Hercules,
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CA). For western blot, after electrophoresis, protein was transferred to a nitrocellulose
membrane using an Xcell II transfer apparatus (Invitrogen, Carlsbad, CA). The
membrane was then probed with 0.5pg/ml of tetra-HIS antibody (Qiagen) in Tris-
buffered saline with 0. I1% Tween-20 and followed by 1:2000 dilution of goat anti-mouse
IgG horseradish peroxidase conjugate (Sigma). Detection was performed with
SuperSignal® substrate from Pierce (Rockford, IL) and Fluor-S imager. In this work,
purified proteins were de-glycosylated with N-glycosidase Endo Hf and PNGase F
according to the manufacturing protocol from New England Biolabs (Beverly, MA)
2.2.5 Binding of the scFv to FOCUS Cells
FOCUS cells were cultured as previously described (Yoon, et al., 2000). FOCUS
cells were detached from the culture plates using versene solution (Gibco, Carlsbad, CA),
and then resuspended in PBS supplemented with lg/L bovine serum albumin (BSA).
ScFv was allowed to bind to the FOCUS cells at 40 C for 4 to 6 hours. The cells were then
washed with PBS/BSA and stained with 1:50 dilution of anti-FLAG-IgG-FITC conjugate
(Sigma) at 40C for 30min. Stained cells were then analyzed by flow cytometry. The scFv
epitope mapping experiment was similarly performed with the exception that excess
amount (10 fold) of AF-20 IgG was added to the initial scFv incubation step. The titration
of AF-20 scFv against FOCUS cells was also performed similarly but with different
secondary detection antibodies. Different concentrations of scFv were incubated with
FOCUS cells at 4"C for 4 to 6 hours, and then the cells were stained with 100nM of
mouse anti-FLAG IgG (Sigma) and followed by 1:50 dilution of goat anti-mouse IgG-
phycoerythrin conjugate (Sigma) for 20min at 40C. Cell fluorescence was then detected
using a flow cytometer.
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2.2.6 Internalization of the AF-20 scFv into FOCUS Cells
Vitrogen from Cohesion Technologies (Palo Alto, CA) was added to a clean
coverslip and subsequently FOCUS cells were cultured on these collagen-coated
coverslips. 200nM of AF-20 scFv or control scFv was pre-incubated with 50nM of mouse
anti-FLAG IgG. After overnight culturing, FOCUS cells were washed, and allowed to
bind the pre-incubated materials in serum-free media at 370C for 1 hour. After the
incubation, cells were fixed with 4% cold formaldehyde (Sigma) for 20min and then
permeabilized with 0.1% saponin (Sigma). The permeabilized cells were labeled with
1:100 dilution of goat anti-mouse IgG-FITC conjugate (Sigma) and 1:10000 dilution of
Hoechst dye (Molecular Probe) at room temperature for 30min. Fluorescence inside the
cells was detected using a confocal microscope. For the internalization study of Quantum
dot, 250nM of AF-20 scFv or control scFv was pre-incubated with 75nM of biotinylated
mouse anti-FLAG IgG and 2L of Qdot 565-streptavidin conjugate (Quantum Dot,
Hayward, CA) in a total volume of 50OL of serum-free media. After I hr of pre-
incubation, the pre-incubated mixture were diluted with 300gL of serum-free media and
presented to the cells grown on coverslip at 37°C for 3hour. Cells were then analyzed
directly using a confocal microscope.
2.2.7 Construction of AF-20 scFv-Gelonin Immunotoxin
AF-20 scFv was fused to the amino terminus of the gelonin to construct the AF-
20 scFv-gelonin immunotoxin. The immunotoxin was constructed and expressed
according to the previous report (Rosenblum, et al., 2003). Briefly, overlapping PCR
products containing the AF-20 scFv/rGel gene were cloned into the bacterial expression
plasmid pET-32a(Novagen). An epitope tag, FLAG, was inserted at the amino terminus
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of the immunotoxin for detection. The AF-20scFv/rGel protein was expressed using the
E. coli strain AD494(DE3)pLysS by induction with 100 jgM IPTG at 230 C for 16 hrs.
Soluble protein was purified using Blue Sepharose 6 Fast Flow and stored in PBD at 40 C.
2.2.8 In-vitro Cytotoxicity of the Immunotoxin
A 72-hr cell proliferation assay with log-phase (5000 to 10000 cells/well) AF-20
antigen-positive cells were performed as described previously (Nishikawa, et al., 1992).
The cells used in this studied were FOCUS cells (HCC), L3.6pl cells (pancreatic tumor)
and PC3 cells (prostate tumor). Cell viability was assessed using either alamarBlueTM
(Biosource, Camarillo, CA) or the previously described crystal violet staining procedures
(Nishikawa, et al., 1992). Cell viability detection using alamarBlue T M was performed
according to the manufacturing protocol.
2.2.9 Display of AF-20 scFv and Binding of AF-20 scFv Displaying Yeasts
For yeast surface display, AF-20 scFv was restriction digested and ligated into
pCTCON vector. The vector was then transformed into EBY100. EBY100 cells carrying
the plasmid was grown in SD-CAA for 24hr and then induced in SG-CAA+0.2% glucose
media for another 24hr. The display level was detected with mouse monoclonal antibody
9e 10 (Covance, Berkeley, CA) and goat anti mouse-phycoerythrin conjugates (Sigma).
FOCUS cells were grown as a monolayer on a coverslip-bottom petri dish
(Mattek, Ashland, MA). 107 yeast cells displaying either no scFv, control scFv or AF-20
scFv were allowed to roll and bind to the monolayer of FOCUS cells respectively at room
temperature for lhr in Dulbecco's PBS (Gibco). Four washes with Dulbecco's PBS were
performed to remove the yeast cells that non-specifically stick to the FOCUS cells. Then
the yeast-FOCUS cells complex were fixed in ice cold 4% formaldehyde for 20min, and
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then washed four times with room temperature PBS. The complex was later imaged using
a light microscope and the number of yeast cells on the FOCUS cells was counted.
2.3 Results
2.3.1 Construction of AF-20 scFv
The variable region genes of the mouse AF-20 IgG were cloned from AF-20
hybridoma cDNA with degenerate PCR primers from the Ig Prime kit (Novagen), and
were sequenced separately. The translated amino acid sequences of the variable regions
of both heavy and light chains are shown in Figure 2.1. The AF-20 scFv was constructed
in the configuration of VH-linker-VL using the splicing by overlap extension (SOE) PCR
method (Horton, et al., 1989; Krebber, et al., 1997), with four repeats of (Gly4-Ser) as
the linker. Two epitope tags were added to the flanking regions of the scFv, a FLAG tag
on the N-terminus and a 6xHis tag at the C-terminus. The epitope tags were later used for
both scFv detection and purification. DNA sequencing of the whole AF-20 scFv gene
construct confirmed that the scFv gene sequence containing both epitope tags was in
frame and contained no mutations. A schematic of the AF-20 scFv is shown in the top
panel of Figure 2.2.
2.3.2 Expression of the AF-20 scFv in Saccharomyces Cerevisiae
The AF-20 scFv gene was subcloned into the pRS based secretion vector (Parekh,
et al., 1995), and the AF-20 scFv was expressed in Sccharomyces cerevisiae strain
YVH10 (Robinson, et al., 1994). Supernatant from the AF-20 scFv secreting yeast was
concentrated and purified using Nickel-NTA resin. The purified AF-20 scFv was then
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A S Q V Q L Q Q S G P D L V K P G A S V
1 gctagccaggtccaactgcagcagtctggacctgacctggtgaagcctggggcttcagtg 60
R I S C K A S G Y T F A G H Y V H W V K
61 aggatatcctgcaaggcttctggctacaccttcgcaggccactatgtacactgggtgaag 120
Q R P G R G L E W I G W I F P G K V N T
121 cagaggcctggacggggacttgagtggattggatggattttccctggaaaggtaaatact 180
K Y N E K F K G K A T L T A D K S S S T
181 aagtacaatgagaagttcaagggcaaggccacattgactgcagacaaatcctccagcaca 240
A Y M Q L S S L T S E D S A V Y F C A R
241 gcctacatgcagctcagcagcctgacctctgaggactctgcggtctatttctgtgcaaga 300
V G Y D Y P Y Y F D Y W G Q G T T L T V
301 gttggatatgattacccgtactactttgactactggggccaaggcaccactctcacagtc 360
S S G G G G S G G G G S G G G G S G G G
361 tcctcaggtggtggtggttctggtggtggtggttctggcggcggcggctccggaggagga 420
G S D I L L T Q S P A I L S V S P G D R
421 ggatcggacatcttgctgactcagtctccagccatcctgtctgtgagtccaggagacaga 480
V S F S C R A S Q S I G T S I H W Y Q Q
481 gtcagtttctcctgcagggccagtcagagcattggcacaagcatacactggtatcagcaa 540
R T N G S P R L L I K Y A S E S I S G I
541 agaacaaatggttctccaaggcttctcataaagtatgcttctgagtCtatCtctggtatc 600
P S R F S G S G S G T D F T L S I N S V
601 ccttccaggtttagtggcagtggatcagggacagattttactcttagcattaacagtgtg 660
E S E D V A D Y Y C Q Q S S S W P F T F
661 gagtctgaagatgttgcagattattactgtcaacaaagtagtagctggccattcacgttc 720
G S G T K L E I K N A D A G G S
721 ggctcggggacaaagttggaaataaaaaatgctgatgctggtggatcc
Protein Sequence: variable domain of heavy chain
QVQLQQSGPDLVKPGASVRISCKASGYTFAGHYVHWVKQRPGRGLEWIGWIFP
GKVNTKYNEKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYFCARVGYDYPYY
FDYWGQGTTLTVSS
Protein Sequence: variable domain of light chain
DILLTQSPAILSVSPGDRVSFSCRASOSIGTSIHWYQQRTNGSPRLLIKYASESISGI
PSRFSGSGSGTDFTLSINSVESEDVADYYCQQSSSWPFTFGSGTKLEIKNA
Figure 2.1 The nucleic acid and amino acid sequences of the variable domains of
AF-20 IgG. Genes of the variable domains were cloned from the AF-20 IgG secreting
hybridoma cells and sequenced. Underlined regions are the corresponding
complementarity-determining regions (CDRs) of the variable domains. N-Glycosylation
occurred on the italic/red asparagine residue during the expression of antibody fragment
in Saccharonyces cerevisiae.
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Figure 2.2 Secretion and Purification of AF-20 scFv. The top panel illustrated the
schematic of the secreted AF-20scFv. Variable domains of heavy chain and light chain
were connected through a (Gly)4-Ser linker, forming a single-chain Fv. Two epitope tags,
n-terminal FLAG and c-terminal 6xHis, were inserted for detection and purification.
Soluble AF-20 scFv was purified using Nickel-NTA resin. Native AF-20 scFv was
glycosylated in Saccharomyces cerevisiae as shown in the middle panel. Purified proteins
were run on SDS-PAGE gel and stained with Coomassie Blue-stain. Unmodified AF-
20scFv migrated at about 40 to 45kDa, which was much higher than the expected size of
30kDa (middle left panel). After being digested in N-glycosidase (PNGase F and Endo
Hf), AF-20 scFv migrated at a smaller size (about 33kDa), which was closer to the
expected size (middle right panel). The asparagine on light chain, where N-glycosylation
occurred (Figure 1), was mutated to aspartic acid. Western blot of the asn-to-asp mutant
supernatant using mouse anti-FLAG IgG-HRP conjugate showed that the AF-20scFv
mutant migrated at about 30kDa (lower left panel). The Coomassie Blue-stained gel on
the lower right panel showed that purified AF-20 scFv mutant (N-,D) also migrated at
about 30kDa and was without any significant contamination from yeast proteins.
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analyzed by SDS-PAGE. The middle left panel of Figure 2.2 shows that purified AF-20
scFv migrated at a size about 40 to 45kDa, which was larger than the expected size of
30kDa. Western blot analysis of the 40kDa band using tetra-HIS antibody (Qiagen)
revealed that the band contained a 6xHis tag (data not shown). The reason for the
aberrant size of the AF-20 scFv was determined to be due to glycosylation in S.
cerevisiae. A consensus N-glycosylation site (asn-gly-ser) is present on the light chain
sequence, and this particular region of the antibody was predicted to be surface exposed
by homology modeling. To investigate the glycosylation status of the scFv, the purified
antibody fragment was incubated with two different N-glycosidases (PNGase F and Endo
Hf) and then examined by SDS-PAGE (Bretthauer and Castellino, 1999). The middle
right panel of Figure 2.2 showed that the N-glycosidase-digested scFv bands migrated at
about 33kDa, which was smaller than the undigested band and closer to the theoretical
size (30kDa). This confirmed that the AF-20 scFv was N-glycosylated during secretion in
Saccharomyces cerevisiae. The Fv model in Figure 2.3 also indicated that the
glycosylation site was close to the junction between variable and constant domains of the
light chain, and on the opposite side from the CDRs. Coomassie gel analysis of the
purified AF-20 IgG showed that the light chain migrated at slightly less than 30kDa, thus
free of glycosylation (data not shown). Therefore, this glycosylation site is likely unique
to the scFv format of the antibody, due to the exposure of this interfacial site upon
construction of the scFv format. This would suggest that removing the glycosylation site
should not significantly alter the binding affinity of AF-20 scFv. In order to prevent the
potential interference of glycosylation on protein expression in Saccharomyces cerevisiae
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Figure 2.3 Homology Model of AF-20 Fv. The AF-20 Fv model was computed using
web antibody modeling (http://antibody.bath.ac.uk). The red and white ribbons are the
framework regions of the light and heavy chains respectively. The CDRs of the light and
heavy chains are shown in blue. The asparagine residue where N-glycosylation occurs is
shown in green, and it is located far away from the CDRs.
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and downstream purification, the asparagine of the Asn-Gly-Ser consensus sequence
(Figure 2.1), was changed to an aspartic acid by site directed mutagenesis. Western blot
analysis of the supernatant of mutated AF-20 scFv (N41D) showed that the scFv
migrated at the expected size of 30kDa (bottom left panel of Figure 2.2). This was further
confirmed by SDS-PAGE of the purified, mutant AF-20 scFv (bottom right panel of
Figure 2.2). In addition, purified AF-20 scFv was free of any major contaminants from
yeast native proteins. This N41D non-glycosylated mutant was used in subsequent
studies.
2.3.3 Binding Epitope and Affinity of the AF-20 scFv against FOCUS Cells
FOCUS cells which overexpress AF-20 antigen were used as a model system to
determine the specificity of the AF20 scFv (Wands, et al., 1997). FOCUS cells were
detached from culture plates using versene solution to protect the integrity of the cell
membrane antigens. FOCUS cells were incubated with buffer alone, nonspecific control
scFv (anti-fluorescein scFv) or AF-20 scFv at 40C. Then the cells were stained with
mouse anti-FLAG IgG-FITC conjugate and analyzed by flow cytometry (FACS). The top
panels of Figure 2.4 showed that the FACS histograms of control (anti-fluorescein) scFv
and no scFv (background) were virtually identical. The bottom left panel of Figure 2.4
shows that AF-20 scFv binds to FOCUS cells. To demonstrate that this binding is
specific, AF-20 scFv was incubated with FOCUS cells in the presence of an excess AF-
20 IgG. Cells were then stained with mouse anti-FLAG IgG-FITC conjugate, which only
recognizes the AF-20 scFv. Figure 2.4 bottom right panel showed that the binding of AF-
20 scFv to FOCUS cells is completely abolished by the addition of AF-20 IgG. This
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Figure 2.4 In-vitro Specific Binding of AF-20 scFv on the Surfaces of FOCUS Cells.
FOCUS cells were detached from the plates and were allowed to bind buffer, control
scFv (anti-fluorescein scFv) or AF-20scFv at 4°C. The cells were then stained with
mouse anti-FLAG IgG-FITC conjugate, which only recognized the FLAG tag on control
and AF-20 scFv, and stained cell were analyzed using FACS. The top left and right
panels showed that control scFv did not bind FOCUS cells, whereas the AF-20 scFv
showed binding against FOCUS cells (lower left panels). With the addition of AF-20
IgG, the binding of AF-20scFv on the surface of FOCUS cells were significantly lowered
(lower right panel). This indicated that the AF-20 scFv bind to the same epitope as the
AF-20 IgG.
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illustrates that AF-20 scFv binds specifically to FOCUS cells, with a binding epitope
competitive with and likely identical to AF-20 IgG. The dissociation constant of AF-20
scFv against AF-20 antigen at 40C was determined. FOCUS cells were allowed to bind to
different concentrations of AF-20 scFv solubly at 40C. The scFv bound cells were then
incubated with mouse anti-FLAG IgG, and followed by staining with goat anti-mouse
IgG-phycoerythrin conjugate. The cell surface fluorescence was analyzed using FACS.
Figure 2.5 shows the titration curves of AF-20 scFv against FOCUS cells at 40 C. The
dissociation constant was determined to be 3.8 +0.7nM at 40C.
2.3.4 Internalization of the AF-20 scFv into Tumor Cells
One of the salient properties of AF-20 antigen is that once AF-20 IgG binds, the
complex is internalized readily (Moradpour, et al., 1995). The ability of the AF-20 scFv
to internalize similarly was studied. FOCUS cells were seeded on collagen plated
coverslips overnight. Control (nonspecific) scFv or AF-20 scFv were pre-incubated with
mouse anti-FLAG IgG, so that the scFv would be presented in a bivalent form to the
FOCUS cells, similar to the AF-20 IgG. Conjugated bivalent scFv were then incubated
with the adhered FOCUS cells for hr at 370C in serum free media. The cells were then
washed, fixed and permeablized. The presence of mouse antibodies inside the cells,
which implied the internalization of scFv, was detected with goat anti-mouse IgG-FITC
conjugate. Cells were also co-stained with Hoechst, a nuclear dye. Stained cells were then
analyzed using a confocal microscope. Figure 2.6 top, left panel showed negligible
internalized green fluorescence signal (FITC) for the control scFv, indicating the absence
of any substantial internalization of control scFv into the FOCUS cells. On the other
hand, the top, right panel of Figure 2.6 showed intense FITC fluorescence surrounding
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Figure 2.5 Titration Curve of AF-20 scFv against FOCUS Cells. FOCUS cells were
first resuspended in solution, and incubated with various concentrations of AF-20 scFv at
4°C. AF-20 scFv bound cells were then stained with mouse anti-FLAG IgG and followed
by goat anti-mouse IgG-PE conjugate. Cell fluorescence was detected with FACS.
Triplicate trials were performed. The data was fit respectively for each trial and the
average dissociation constant of the AF-20 scFv against FOCUS cell at 40C was
determined to be 3.8 ± 0.7nM.
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Figure 2.6 In-vitro Internalization Study of AF-20 scFv into FOCUS Cells. The
abilities of the AF-20scFv to internalize by itself and to facilitate the internalization of
other particles into the tumors cells were studied.. FOCUS cells were used in both studies.
For the self-internalization study, mouse anti FLAG 1gG conjugated AF-20 scFv or
control scFv were incubated with the FOCUS cells at 370 C in serum-free media for 1 hr.
Cells were then fixed, permeabilized, and stained with goat anti-mouse gG-FITC
conjugate and Hoechst dye. The green fluorescence beside the nuclei in the top right
panel showed that conjugated AF-20 scFv internalized readily into the FOCUS cells in
vitro. There was no significant green fluorescence signal in the control scFv experiment
(top left panel), indicating the lack of internalization of control scFv. For the facilitated
internalization study, quantum dot Qdot565 was used as the model particle. The AF-20
scFv or control scFv was pre-incubated with biotinylated mouse anti-FLAG IgG and
Qdot 565-streptavidin conjugate. Adhered FOCUS cells were then incubated with the
pre-incubated materials and Hoechst dye at 370C in serum-free media for I hr. The
absence of red fluorescence in the control scFv experiment (bottom left panel) indicated
that there was no facilitated internalization of quantum dot into the FOCUS cells by
control scFv. Whereas the red fluorescence in the bottom right panel showed that AF-20
scFv was able to facilitate the internalization of nano-scale particles, quantum dots, into
FOCUS cells. The blue fluorescence was from the Hoechst staining of the nuclei.
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the nuclei of the cells, suggesting that the bivalent AF-20 scFv internalized readily into
the FOCUS cells, just as AF-20 IgG did. However, when AF-20 scFv was presented
monovalently to the FOCUS cells, the extent of internalization was significantly reduced,
signifying the importance of bivalency in the rapid internalization of the antibody.
2.3.5 Facilitated Internalization of Nano-scale Particles
The ability of the AF-20 scFv to internalize into the tumor cells could be
employed to deliver virus or liposome particles carrying suicide gene into tumor cells for
gene therapy (Haisma, et al., 2000; Kashentseva, et al., 2002; Mohr, et al., 2000;
Nettelbeck, et al., 2004; Yoon, et al., 2000). Virus or liposome particles in this case are
considerably larger than the AF-20 scFv protein. The ability of the AF-20 scFv to
facilitate internalization of much larger particles into tumor cells was examined. Quantum
dots conjugated to streptavidin (Qdot 565) were used as model particles in this study.
This particle is about 30nm in diameter and comparable in size to a viral particle. AF-20
scFv or control scFv (anti-fluorescein) was pre-incubated with biotinylated mouse anti-
FLAG IgG and Qdot 565-streptavidin conjugate. The pre-incubated materials were then
incubated with FOCUS cells at 37°C in serum free media for 3 hr. Cells were also co-
incubated with the Hoechst dye. Internalized quantum dots, which emit red fluorescence
upon excitation at 565nm, were detected by confocal microscopy. The control scFv did
not facilitate the internalization of quantum dots (bottom left panel of Figure 2.6), as
there was negligible red fluorescence inside the cells. However in the AF20 treated
samples there was considerable red fluorescence inside the cells (bottom right panel
Figure 2.6). These results indicate that the AF-20 scFv is able to facilitate internalization
of a nano-scale particle.
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2.3.6 In-vitro Cytotoxicity of AF-20 Gelonin Fusion Construct
The capability of AF-20 scFv to serve as the targeting domain in an immunotoxin
construct was studied. The toxin used in this study was recombinant gelonin, a highly
cytotoxic ribosome-inactivating protein (Falasca, et al., 1982). It was previously shown
that fusing a targeting scFv or a growth factor to gelonin greatly improved the cell-killing
efficacy of gelonin both in vivo and in vitro (Rosenblum, et al., 2003). Therefore, AF-20
scFv-gelonin fusion were constructed as previously reported to determine if the addition
of AF-20 scFv to gelonin would similarly improve the efficacy of gelonin (Rosenblum, et
al., 2003). The AF-20 scFv/rGel purified protein was confirmed to have the same binding
affinity as AF-20 scFv at 40C, indicating that the AF-20 scFv domain was properly folded
and fully functional (data not shown). The in vitro cytotoxic effects of the AF-20
scFv/rGel fusion toxin and free rGel were assessed and compared on three different
tumor cell line. The tumor cells lines employed in this study were FOCUS cells, L3.6pl
cells and PC3 cells, which are liver, pancreatic and prostate cancer cell lines respectively.
Log-phase cells (5000 to 10000 cells per well) were seeded in 96-well plates overnight,
and then exposed to various concentrations of AF-20 scFv/rGel fusion and free rGel
respectively. After the treatment, cell viabilities of the treated cells and the untreated
positive control cells were determined either using Alamar Blue stain or crystal violet
stain. Figure 2.7 showed that in the case of FOCUS cells, the IC50 value for AF-20
scFv/rGel was approximately 100 to 200nM; whereas the IC50 value for free rGel was
about 2gM, one log higher than the IC50 of AF-20 scFv-gelonin fusion. As for the L3.6pl
cells, the IC50 value for AF-20 scFv-gelonin was approximately 35nM; meanwhile the
IC5o value for the free gelonin was about I pM. For the PC3 cells, the IC5o value for AF-
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Figure 2.7 Comparative In-vitro Cytotoxicity of the Free Gelonin and AF-20
scFv/rGel Fusion Construct on FOCUS, L3.6pl and PC3 Cells. Different tumor cell
lines (FOCUS, L3.6pl and PC3) were plated and treated with various concentrations of
free rGel or AF-20 scFv/rGel fusion construct respectively. Cell viabilities were detected
using Alamar blue stain (FOCUS) or using crystal violet dye (L3.6pl and PC3). For the
FOCUS cells, the IC50 values for AF-20 scFv/rGel and free rGel were about 100nM and
2jiM respectively. For the L3.6pl cells, the IC5o values for AF-20 scFv/rGel and free rGel
were about 35nM and ltM respectively. As for the PC3 cells, the IC50 values for AF-20
scFv/rGel and free rGel were about 3.5nM and 100nM respectively. The IC5o value for
AF-20 scFv/rGel was consistently shown to be one to two logs lower than the IC5o value
for free rGel on three different cell lines.
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20 scFv-gelonin was approximately 3.5nM, while the IC50 value for free gelonin was
about 100nM. The IC50 value for AF-20 scFv-gelonin was consistently one to two logs
lower than the IC50 value for free gelonin. This illustrates that the AF-20 scFv can
function as a targeting module in the construction of immunotoxins.
2.3.7 Display of AF-20 scFv on the Yeast Surface
The AF-20 scFv was ligated into the display plasmid, which contained both the
HA and the c-myc tags, and subsequently, the plasmid was transformed into yeast. The
transformed yeast cells were then induced to display the AF-20 scFv on the cell surface.
The expression of the AF-20 scFv was detected by first labeling the induced yeast cells
with mouse antibody 9e 10, followed by staining the yeast cells with goat anti-mouse IgG-
phycoerythrin (PE) conjugate. Figure 2.8 showed the histograms of the PE fluorescence
level for both induced and non-induced yeast populations. The non-induced yeast
population, which did not display any AF-20 scFv, has negligible level of PE signal;
whereas the yeast population displaying the AF-20 scFv showed a high level of PE
intensity. The high level of PE signal implied the expression of AF-20 scFv on the yeast
surface. It is common for induced yeast cultures to contain a negative population due to
loss of the display plasmids during growth and induction. However, in general, this
negative population is only a minor portion of the total population and does not interfere
with the detection and screening processes. The expression of AF-20 scFv on the yeast
surface also suggests that the scFv is well folded on the yeast surface.
2.3.8 Binding of AF-20 Displaying Yeasts against FOCUS Cells
After confirming the AF-20 scFv is well expressed on yeast surfaces, binding of
these AF-20 scFv-displaying yeast cells to the FOCUS cells were evaluated. As soluble
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Figure 2.8 FACS Histogram of the AF-20 scFv Expression on Yeast Surface. The c-
myc tag of the non-induced and induced yeast populations was labeled and stained with
PE-conjugated antibody. The high level of PE signal for the induced yeasts indicated that
the AF-20 scFv was expressed and folded properly on the surface of yeast. Meanwhile,
the non-induced (control) yeast population, which did not display the AF-20 scFv, had
negligible level of PE signal.
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AF-20 antigen is not available yet, the formation of the yeast-FOCUS cell complex was
used to determine the binding of AF-20 scFv to its antigen. FOCUS cells were grown as a
monolayer on a coverslip. A non-displaying yeast population and yeast populations
displaying either AF-20 scFv or a control scFv were allowed to roll and bind to the
monolayer of FOCUS cells respectively at room temperature. Several washes were
performed to remove the yeast cells that non-specifically stick to the FOCUS cells. Then
the yeast-FOCUS cells complex were fixed and imaged using a light microscope. Figure
2.9 showed the images of the yeast-FOCUS cells complexes with both the AF-20 scFv-
displaying yeast population and non-displaying yeast population. The top right panel of
Figure 2.9 showed that there are high levels of yeast-FOCUS cell complex formation
with the AF-20 scFv-displaying yeast population, whereas a minimal amount of
complexes was detected in the case of the non-displaying yeast population. Similarly,
minimal amount of complexes were formed with cells that displaying the control scFv
(data not shown). Quantitative measurements of the number of yeast cells on the FOCUS
cell surface at multiple areas of the coverslip showed that yeast-FOCUS cells complex
formation was significantly higher for the AF-20 scFv displaying yeast population than
for the non-displaying yeast population or the yeast population displaying the control
scFv. This indicated that the AF-20 scFv displaying on the yeast surface was functional
and responsible for the binding of the yeast cells to the FOCUS cells.
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Figure 2.9 Formations of Yeast-FOCUS Cells Complexes. Yeast cells that did not
display any scFv and yeast cells displaying either control scFv or AF-20 scFv were
allowed to bind respectively to a monolayer of FOCUS cells. After several washes,
amount of yeast cells that were retained on the FOCUS cells were imaged and counted.
The top left image showed that high numbers of AF-20 scFv displaying yeast cells were
retained on the FOCUS cells surface, whereas as shown in the top right figure, negligible
amount of the non-displaying yeast cells were captured on the FOCUS cells surface.
Three images were taken at different regions of coverslip for each case. The number of
retained yeast cells on each image was counted. Quantitative measurements showed that
AF-20 scFv displaying yeast cells is retained at a significantly higher level than those of
non-displaying yeast cells and control scFv displaying yeast cells on the surfaces of
FOCUS cells.
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2.4 Discussion
In this study, we cloned the variable region genes of the AF-20 IgG and used the
genes to construct a scFv. The AF-20 scFv was shown to retain the same binding and
internalization ability as the IgG format, and also shown to facilitate the internalization of
virus-scale particles into tumor cells. In addition, the AF-20 scFv was demonstrated to be
an effective targeting domain for the construction of immunotoxin. This AF-20 scFv is a
candidate for targeting toxins, enzymes, radionuclides, liposomes or virus for targeted
therapy.
One of the tumors AF-20 IgG has been shown to target is HCC, for which common
cancer therapies are ineffective. Immunotherapy using AF-20 antibody would present an
alternative option for the treatment of HCC. Targeting internalization epitopes has been
previously shown to improve the targeted delivery of liposome into lymphoma cells over
targeting non-internalization epitope (Sapra and Allen, 2002). Prior experiments using
AF-20 gG as the targeting molecule have been performed and shown to be successful.
Different AF-20 conjugated moieties like liposome and virus carrying therapeutic genes
has been delivered to the liver tumor cells in vitro. Since, as shown in this study, the AF-
20 scFv binds to the same epitope as the AF-20 IgG and internalized similarly as AF-20
IgG, it is expected that the AF-20 scFv could substitute in the previous applications
involving AF-20 IgG, specifically targeting viral or other particles to the liver tumor
cells. This is further confirmed by our result that AF-20 scFv was able to facilitate
internalization of nano-scale particle into the tumor cells. Thus, this AF-20 scFv has the
potential to deliver to the cytoplasm of target cells various cytotoxic payloads.
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We found that the monovalent format of AF-20 scFv did not internalize as readily
as the bivalent format of AF-20 scFv in vitro. The identity of the AF-20 antigen is as yet
unknown. Perhaps dimerization of the receptor by the bivalent format of antibody is
required for rapid internalization of the complexes. One example of this type of bivalent-
activated internalization is an antibody, MGR2, targeting the extracellular domain of
pl85HER2, a transmembrane glycoprotein coded by the HER2/neu oncogene (Srinivas,
et al., 1993). Srinivas and co-workers showed that MGR2 IgG induced internalization in
two cell lines overexpressing the p185HER2 receptor; whereas the MGR2 Fab targeting
the same epitope was not internalized. However, when MGR2 Fab fragment was
conjugated using a rabbit anti-mouse IgG to give a bivalent format, internalization was
observed. This is similar to our previous observations in the case of AF-20 scFv,
illustrating that bivalency is important for the rapid internalization of the antibody.
Immunotoxins have been used in both laboratory and clinical settings to kill cancer
cells. Different protein toxins including Pseudomonas exotoxin, Diphtheria toxin,
gelonin, ricin A chain, as well as small molecule toxins such as maytansinoids and
caliecheamycins have been either chemically conjugated or genetically fused to different
antibodies to construct immunotoxins and immunochemotherapeutics (Bera, et al., 1999;
Hexham, et al., 2001; Ma, et al., 2001; Rosenblum, et al., 2003; Safavy, et al., 2003;
Thompson, et al., 2001). In this work, we have constructed an immunotoxin consisting of
AF-20 scFv and rGel, and demonstrated the improved efficacy of AF-20 scFv
immunotoxin over free rGel on three different tumor cell lines. The IC50 of the AF-20
immunotoxin was about 3.5nM and 35nM for L3.6pl and PC3 cells respectively.
Previously, a similar scFv-gelonin immunotoxin was constructed to treat melanoma cells,
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and the IC50 for that particular immunotoxin is about 8nM in vitro (Rosenblum, et al.,
2003). Meanwhile, the IC50 of AF-20 gelonin for FOCUS cells is on the order of 100nM,
which is significantly higher than the IC50 of other cell lines. One potential reason could
be the differences in gelonin responses among the cell lines used. There were previous
reports showing that tumor cells could develop resistance to gelonin (McGrath, et al.,
2003; Rosenblum, et al., 1996). One distinct feature of these gelonin-resistance cells is
that these cells specifically shuttle the internalized toxin into the lysosome (McGrath, et
al., 2003). To this end, we investigated whether disrupting the lysosome would improve
the efficacy of the immunotoxin on FOCUS cells. We incubated the FOCUS cells
simultaneously with the toxins and 100,tM chloroquine, a lysosomotropic agent, for four
hours, and the cell viabilities of the treated cells and untreated positive control cells were
recorded. The IC50 of the AF-20 scFv-gelonin was enhanced to about 0.4nM, while the
IC 0o of the gelonin was also lowered to about 40nM (bottom panel of Figure 2.10). Under
the influence of chloroquine, the extent of improvement for free gelonin was 10 fold less
than the extent of improvement for AF-20 scFv-gelonin. Meanwhile, there was no
observable change in the viability of the chloroquine-exposed control cells, compared to
the non-exposed control cells (top panel of Figure 2.10).
Microscopic studies also confirmed that the internalized bivalent AF-20 scFv co-
localized with the lysosome, indicating that AF-20 scFv was transported into lysosome
(Figure 2. 1). The efficacy improvement by disrupting lysosome has also been observed
with an immunotoxin directed against murine B cells. May et al. showed that in the
presence of chloroquine, the less potent immunotoxin became 100 fold more potent,
concluding that intracellular routing is important in determining the efficacy of the
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Figure 2.10 In-vitro Cytotoxicity of AF-20/rGel under the Influence of Chloroquine.
FOCUS cells were simultaneously incubated with the AF-20-gelonin toxin and
chloroquine, and cell viabilities of the treated cells and untreated positive control cells
were recorded. The top panel shows that there is no observable change in the viability of
the chloroquine-exposed control cells, compared to the non-exposed control cells, thus
the chloroquine treatment under the experimental conditions were not toxic to the cells.
The bottom panel shows that the IC50 of the AF-20 scFv-gelonin is enhanced to about
0.4nM, while the IC50 of the gelonin is also lowered to about 40nM. Under the influence
of chloroquine, the extent of improvement for free gelonin (2gM to 40nM) was about 10
fold less than the extent of improvement for AF-20 scFv-gelonin (200nM to 0.4nM),
indicating that the efficacy of AF-20/rGel can be improved if lysosomal trafficking is
avoided.
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Figure 2.11 Co-localization of AF-20 scFv and Lysosome. Alexa-488 labeled AF-20
scFv was conjugated using mouse anti-FLAG IgG. The conjugated antibodies along with
the red LysoTracker dye (Molecular Probe) were incubated with the FOCUS cells at 4°C
or 37''C in serum-free media. Images were taken with a deconvolution microscope. At
4°C, the scFv (green) primarily resides on the outside of the cells, and does not co-
localize with the lysosome (red dots inside the cells). However, at 37°C, the AF-20 scFv
is internalized and co-localized with the lysosome (yellow), indicating that the AF-20
scFv is shuttled into the lysosome.
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immunotoxin (May, et al., 1991). Their results were similar to the results of the AF-20
scFv-gelonin on FOCUS cells. However, in a clinical setting, it is difficult to pre-treat the
tumors with any lysosomotropic agent. A potential remedy may be to incorporate into
the immunotoxin a peptide or polymer that is capable of inducing endosomal escape.
These endosomal escape entities will enable more efficient delivery of the toxin into the
cytosol, potentially improving the efficacy of the immunotoxin on HCC and other
gelonin-resistant tumor cells (Akinc and Langer, 2002; Panyam, et al., 2002; Van
Rossenberg, et al., 2002; Wadia, et al., 2004).
Another potential way to improve the efficacy of the AF-20 immunotoxin would
be to increase the avidity of the AF-20 targeting module, hence the affinity of AF-20
immunotoxin toward tumor cells (Thompson, et al., 2001). In addition, our internalization
study showed that the divalent AF-20scFv internalized much faster than monovalent AF-
20 scFv. We would expect higher amount of immunotoxin delivered to the cells by using
the divalent immunotoxin, thereby exhibiting higher efficacy. Surprisingly, this was not
the case. Instead of presenting the immunotoxin to the tumor cells in a monovalent
format, AF-20 immunotoxin, which contained an FLAG tag, was artificially conjugated
using a mouse anti-FLAG IgG to form a bivalent immunotoxin. However, our study
showed that the conjugated immunotoxin did not demonstrate any significant efficacy
improvement over the monovalent fusion toxin as assessed on two different cell lines
(data not shown). One reason for the lack of efficacy improvement could be due to high
antigen density. Bera and co-workers showed that the bivalent e23 dsFv immunotoxin,
targeting erbB3, was 9-29-fold more cytotoxic than the corresponding monovalent dsFv
immunotoxin on cells expressing relatively low amounts of erbB2 (A43 1, MCF7, HepG2,
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and LNCP) (Bera, et al., 1998). However, improved cytotoxicity of the bivalent
immunotoxin was not evident on cells overexpressing erbB2 antigen, such as SK-BR-3
and N87 cells, although the bivalent immunotoxin did bind to both A431 and N87 cells
with higher affinity than the monovalent immunotoxin (Bera, et al., 1998). Therefore,
antigen density could be one of the factors affecting the difference between monovalent
and divalent immunotoxins. Another possible factor is the trafficking properties of the
monovalent and divalent immunotoxin, which were described in the previous paragraph.
Other studies have also shown that trafficking properties played an important role on
determining the efficacy of the immunotoxin (Yazdi, et al., 1995). Further study is
needed to determine the trafficking properties of the monovalent and bivalent
immunotoxin.
The AF-20 V gene can be fused to various moieties to develop alternative
applications. One potential application is in tumor imaging. Different antibody fragments
like scFv, diabody, and minibody can be constructed for targeting tumors and have been
shown to perform better than its IgG counterpart (Adams, et al., 1993; Bera, et al., 1998;
Hu, et al., 1996; Kikuchi, et al., 2004; Wu and Yazaki, 2000). Specifically, due to its
small size (around 30kDa), scFv has been shown to penetrate tumors rapidly and have
rapid clearance from serum and normal tissue, leading to excellent tumors to normal
organs ratios (Kuan, et al., 1999). However, the rapid clearance also renders the absolute
quantity of scFv retained on the tumor to be low. Diabody or minibody, that is
significantly larger than scFv, has higher tumor uptake by avoiding the rapid first-pass
clearance from the circulation. Compensating poor penetration with slower clearance and
potential avidity effect, diabody has also been shown to be as successful a molecule, if
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not better, as scFv targeting cells in vivo (Adams, et al., 1993; Adams and Schier, 1999;
Adams, et al., 1998; Nielsen, et al., 2000; Viti, et al., 1999). In the future, different AF-20
fragment like AF-20 diabody or AF-20 minibody could be constructed for tumor
imaging.
Overall, this study showed that AF-20 scFv is an effective module to target a
variety of AF-20 antigen-expressing tumor cells. Potentially, AF-20 scFv could be
humanized in the future if immunogenicity is a concern for long-term therapeutic
applications (Kettleborough, et al., 1991; Roguska, et al., 1994). With the V gene of the
AF-20 antibody, other tumor targeting or killing modules could be easily constructed.
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Chapter 3: Isolation and Engineering of Human Antibodies
against Human Aspartyl (Asparaginyl) P-Hydroxylase
3.1 Introduction
Over-expression of the enzyme human aspartyl (asparaginyl) P-hydroxylase
(HAAH) has been detected in a variety of cancers including lung, liver, colon, pancreas,
prostate, ovary, bile duct and breast (Lavaissiere, et al., 1996; Palumbo, et al., 2002;
Sepe, et al.. 2002). It is proposed that upon cellular transformation, HAAH is
overexpressed and translocated to the cell surface (Lavaissiere, et al., 1996). HAAH
belongs to the uo-keto-glutarate-dependent dioxygenase family of prolyl and lysyl
hydroxylase (Gronke, et al., 1989; Hanauske-Abel and Popowicz, 2003). In normal cells,
HAAH primarily resides in the endoplasmic reticulum and is involved in post-
translational modification of specific proteins via hydroxylation of specific aspartate or
asparagine residues in EGF-like domains (Gronke, et al., 1989; Przysiecki, et al., 1987).
Consensus hydroxylation sequence contains the amino acids Asp, Asp/Asn, Asp/Asn, and
Tyr/Phe at defined positions, and hydroxylation occurs at the third Asn/Asp in the
consensus sequence. Examples of proteins that contain this consensus sequence are
clotting factor (Gronke, et al., 1989), Notch receptor and ligands (Rebay, et al., 1991),
and extracellular matrix proteins (Downing, et al., 1996). The HAAH protein can be
divided into four distinct domains: a cytoplasmic amino terminal domain, a
transmembrane domain, a highly negative charged domain that projects into the lumen of
the endoplasrnic reticulum, and a catalytic carboxyl terminal domain which is responsible
for the enzymatic activity of HAAH (Jia, et al., 1994; McGinnis, et al., 1996). Another
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protein, Humbug (Junctate), is also produced from the same HAAH locus through
alternative splicing of the mRNA transcript (Dinchuk, et al., 2002). Humbug is a
truncated form HAAH, lacking only the HAAH catalytic domain. Humbug, which cannot
hydroxylase protein, is proposed to be involved in cellular calcium homeostasis (Treves,
et al., 2000).
The detailed biological role of HAAH in tumor formation in vivo is still under
investigation. Previous in vitro and in vivo studies have been performed to shed light on
the biology of HAAH in malignant transformation. Ince and co-workers showed that in
vitro overexpression of enzymatically active HAAH in NIH-3T3 cells was able to induce
malignant transformation in cell culture, increase cellular motility and invasiveness, and
establish tumor formation in vivo (Ince, et al., 2000). In addition, increased HAAH
expression also led to enhanced cell motility and proliferation in neuroblastoma cell lines
in vitro (Sepe, et al., 2002). It was also shown that the expression level of HAAH
correlated with the migratory potential of the cells. High HAAH expression was observed
in proliferating term placental trophoblasts (Lavaissiere, et al., 1996) and in the tumor
infiltrating margins that interfaced with uninvolved tissue (Maeda, et al., 2004). HAAH
expression was also demonstrated to correlate with tumor size, vascular invasion and
poor prognosis (Maeda, et al., 2004). Therefore, HAAH was proposed to play a direct,
activating role in malignant transformation and tumor aggressiveness (Ince, et al., 2000).
A striking observation is that a variety of tumor cells express this particular protein on
their surface. This enzyme is highly specific for cancer and has been detected by
immunohistochemistry in more than 99% of 1000 tumor specimens (unpublished data),
and has minimal expression on the surfaces of normal tissues (Lavaissiere, et al., 1996).
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Due to the highly specific nature of HAAH expression on tumor cell surfaces, it is an
attractive target for cancer immunotherapy.
Previously, several mouse monoclonal antibodies targeting HAAH have been
isolated (Dinchuk, et al., 2002; Wilson, et al., 1988), however murine antibodies are
undesirable for therapeutic use in human due to immunogenicity. Therefore, human
antibodies targeting HAAH are desired for anti-HAAH immunotherapy. In this work,
fully human single-chain Fv fragments (scFv) against HAAH were isolated using a
human non-immune antibody fragment library displayed on yeast surface. Five of these
isolated scFv were reformatted into human IgG. Two of the IgGs, 6-22 and 6-23, were
shown to have significant binding to tumor cell lines. In addition, 6-22 IgG, targeting the
catalytic domain of HAAH, was also shown to internalize into tumor cells and facilitate
the internalization of toxin into the tumor cells. Furthermore, 6-22 scFv was affinity
matured to become a sub-nanomolar HAAH binder using different mutagenesis methods.
Overall, these human anti-HAAH antibodies can potentially be useful for immunotherapy
targeting HAAH-expressing tumor cells.
3.2 Materials and Methods
3.2.1 Cell L,ines and Materials
The non-immune human scFv library used to isolate anti-HAAH binders has been
previously described (Feldhaus, et al., 2003). Cell lines COS-7L and H460 were
purchased from Invitrogen (Carlsbad, CA) and American Type Culture Collection
(ATCC) respectively. Liver tumor cell line, FOCUS, was previously isolated (He, et al.,
1984). Magnetic colloid used for library screening was acquired from Miltenyi Biotech
(Auburn, CA). Mouse antibodies FB-50 and 15c7 were purified from previously isolated
56
hybridoma cells (Wilson, et al., 1988). Mouse anti-c-myc antibody 9e10 was obtained
from Covance (Princeton, NJ). Fluorophores streptavidin-phycoerythrin, goat anti-mouse
IgG-Alexa 488 and goat anti-mouse IgG-phycoerythrin, and also rabbit anti-Alexa 488
IgG were purchased from Molecular Probe (Eugene, OR). Meanwhile, goat anti-human
IgG-phycoerythrin conjugate was obtained from Rockland (Gibertsville, PA). The IgG1
plasmid was a kind gift from Pacific Northwest National Laboratory. Goat anti-human
IgG-peroxide conjugate and non-relevant control human IgG were acquired from Sigma-
Aldrich (St. Louis, MO). ImmunoPure immobilized Protein A plus resin, binding buffer,
elution buffer and Supersignal® ELISA maximum sensitivity substrate were obtained
from Pierce (Rockford, IL). Immunotoxin, goat-anti-human IgG-saporin conjugate, was
purchased from Advanced Targeting System (San Diego, CA).
3.2.2 Isolation of Anti-HAAH Leads
Six rounds of screening were performed to isolate a-HAAH binders from 3 x 109
human scFv-displaying yeasts. First two rounds of screening were carried out with
magnetic colloids (Miltenyi) according to the manufacturing protocol. Briefly, cells were
incubated with 300nM of biotinylated recombinant full-length HAAH protein at room
temperature for 2hr, and then washed, chilled on ice and incubated with magnetic colloid
at 4C for 20min. After the incubation, cells were washed and binders (positive fraction)
were isolated using Auto-MACS (Miltenyi). Collected yeast cells were then expanded in
SD-CAA media and subsequently induced in SG-CAA media for another round of
screening (Boder and Wittrup, 1997). After two rounds of magnetic screening, four
rounds of fluorescence-activated cell sorting (FACS) were performed. Yeasts cells were
co-incubated with 300nM of biotinylated HAAH and 1:100 of 9el0 antibody at 370C in
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PBS containing 1% bovine serum albumin (PBS/BSA). Cells were then washed with cold
PBS/BSA, and co-labeled with 1:100 of streptavidin-phycoerythrin and 1:100 goat anti-
mouse IgG-Alexa 488 in PBS/BSA at 4C for 20min. Cells that have the highest 1%
binding-to-display signal ratio were collected using FACS. These cells were then grown
in SD-CAA and later induced for another round of screening. Three rounds of screening
at 300nM of biotinylated HAAH and one final round of screening at 100nM of
biotinylated HAAH were performed to isolate binders. In between rounds of screening
against biotinylated HAAH antigen, cells were also labeled with just fluorophores
streptavidin-phycoerythrin and goat anti-mouse IgG-Alexa 488 to eliminate fluorophores-
binding clones using FACS. To confirm the binding against HAAH instead of
biotinylation epitope, individual sorted clones was incubated with 300nM of unmodified
full-length HAAH at 370 C, and then washed and labeled with either 200nM of FB-50 or
15c7 on ice for 20min. The binding was detected with goat anti-mouse IgG-
phycoerythrin conjugate and then analyzed by flow cytometry.
3.2.3 Conversion of scFv to IgG
The IgG 1 plasmid contains the constant domains of the human heavy and light
chains. The variable regions of the isolated a-HAAH scFv were PCR out using primers
targeting the light chain and heavy chain of the scFv. For example, for 6-22 IgG, heavy
chain primers 5'-gatcgagcaacgcgtgtcttgtcccaggtacagctgcagcagtcagg-3' and 5'-gatcgag
cagctagctgaggagacggtgaccagggttcc-3', and light chain primers 5'-tcacggtgcacgatgtgagcc
tgtgctgactcagtcaccc-3' and 5'-tcacgcaccgtacgtaggacggtcagcttggtcccag-3' were used. PCR
reaction was carried out with Vent polymerase for 20 cycles according to the
manufacturing protocol. The PCR products were then gel-purified. Heavy chain products
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were restriction digested with Mlul and NheI, and light chain products were digested with
BsiWI and DrallI. The IgG backbone was also digested with the same four enzymes, and
then the digested heavy and light chain PCR products were ligated sequentially into the
digested backbone. The ligated plasmid was then transformed into E.coli for
amplification.
Sixty microgram of plasmid per T-175 flask were used to transfect fully confluent
COS-7L cells using lipofectamine 2000 (Invitrogen) according to the manufacturing
protocol. Transiently transfected cells were cultured in Opti-MEM (Invitrogen) for up to
2 weeks and media containing the secreted IgG was replaced every two days. The media
was then concentrated, buffer-exchanged with ImmunoPure IgG binding buffer and
purified using the Protein A resin according to the manufacturing protocol. Purified IgG
was then dialyzed in PBS and resolved in a denaturing, reduced 12% Tris-Glycine gel.
The gel was stained with SilverXpress® silver staining kit (Invitrogen) according to the
manufacturing protocol.
3.2.4 ELISA
Either 0.3[tg of recombinant full-length HAAH, 0.3gtg of BSA or 0.41tg of
catalytic don-lain of HAAH was coated on the well of a 96-well plate overnight at 40 C.
The coated wells were then blocked with PBS/3% BSA/0.05% Tween20 for 2hr at 4°C,
washed and incubated with various antibodies in PBS at room temperature for 2hr. The
plates were washed with cold PBS/0.1% Tween20 and then incubated with 1:1000 of
goat anti-human peroxide conjugate in PBS at 40 C for 30min. The binding was detected
with Supersignal® ELISA maximum sensitivity substrate and a luminescence plate
reader.
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3.2.5 Binding of the IgGs to Tumor Cells
FOCUS cells were cultured as previously described (He, et al., 1984). H460 cells
were cultured in RPMI with 10% fetal bovine serum (FBS), 2mM glutamine, 100U/ml of
penicillin and 100pg/ml of streptomycin under 5% CO, at 37°C. Cells were dissociated
from the culture plates using cell dissociation solution (Sigma). Cells were then washed
with PBS/BSA supplemented with 2% FBS (PBS/BSA/FBS). lx105 to 2x105 cells were
incubated with various concentrations of antibodies in PBS/BSA/FBS at 40C for 3 to 5hr.
After the incubation, cells were washed, stained with 1:100 of goat anti-human IgG-
phycoerythrin conjugate at 4C for 30min, and finally resuspended in lgg/ml of
propidium iodide solution, used in this case as a marker of non-viable cells. Cell
fluorescence was analyzed using a flow cytometer.
3.2.6 Immunohistochemistry
Paraffin-embedded specimens of primary pancreatic ductal adenocarcinoma and
adjacent chronic pancreatitis tissues were studied. The sections (5-gm thick) were
deparafinized in xylenes and rehydrated in alcohol solutions. Endogenous peroxidase
activity of the tissues was quenched with 0.6% hydrogen peroxide in 60% methanol.
Then the tissues were equilibrated in Tris-buffered saline (TBS, pH7.2), blocked with
horse serum at room temperature, washed, and incubated overnight with 10nM of 6-22
IgG at 4"C in a humidified chamber. The sections were then immunostained with 1:1000
of goat anti-human IgG-peroxide conjugate at room temperature for 30min and
developed with peroxidase stain DAB from the Vector lab (Burlingame, CA).
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3.2.7 Internalization Studies of 6-22 IgG
6-22 IgG was labeled with Alexa-488 molecule using the Alexa Fluor® 488
protein labeling kit (Molecular Probe). FOCUS cells were grown on coverslips and 30nM
of Alexa-488 labeled 6-22 IgG was incubated with the cells either at 40C or 37°C for 4hr
in media. Cells were also stained with 1:1000 of Hoechst dye (Molecular probe). Cells
were then washed and imaged using a deconvolution microscope.
For the study of internalization kinetics, FOCUS cells were cultured in 96-well
plates, and 60nM of Alexa-488 labeled 6-22 IgG or control Alexa-488 conjugated
antibody was incubated with the cells for various times at 37°C in media. At each time
point, cells from a single well were trypsinized at 37°C for 5min to dissociate the cells
firom the well and to remove any surface labeling. Separate experiment was performed to
confirm that 37°C trypsinization was able to remove surface labeling of Alexa 488-6-22
IgG. Trypsinized cells were then washed, resuspended in 1 tg/ml of propidium iodide
solution, and fluorescence inside the cells was analyzed using a flow cytometer. For the
recycling studies, FOCUS cells, cultured in 96-well plates, were pulsed with 60nM of
Alexa-488 labeled 6-22 IgG for 3hr at 370C. After the pulse, cells were washed, chilled,
surface-quenched with 20jig/ml of rabbit anti-Alexa 488 IgG at 40C for 30min, and then
warmed back to 370 C under the continuous presence of quenching antibody for various
times. At different times, cells were trypsinized, resuspended in lgg/ml of propidium
iodide solution, and then analyzed using a flow cytometer.
3.2.8 Cytotoxicity of 6-22 Immunotoxins
The toxin used in this study was goat-anti-human IgG-saporin conjugates.
FOCUS cells were cultured in 96-well plates. 10nM of 6-22 IgG or control antibody was
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pre-incubated with 22nM of goat-anti-human IgG-saporin at room temperature. The
complexes or 6-22 IgG alone was presented to the FOCUS cells. After 3 days of
treatment, the viability of the cells was determined using alamarBlue® dye according to
the manufacturing protocol (Biosource, Camarillo, CA).
3.2.9 Construction of Random Mutagenesis Library
Mutagenic PCR of anti-HAAH scFv was performed using the nucleotide
analogues 8-oxo-2'-deoxyguanosine-5'-triphosphate (8-oxodGTP) and 2-deoxy-P-
nucleoside-5'triphosphate (dPTP), which were both purchased from TriLink
Biotechnologies (San Diego, CA) (Zaccolo and Gherardi, 1999; Zaccolo, et al., 1996).
The forward primer (HA primer) was 5'-CGACGATTGAAGGTAGATACCCATAC
GACGTTCCAGACTACGCTCTGCAG-3' and reverse primer (c-myc primer) was 5'-
CAGATCTC'GAGCTATTACAAGTCTTCTTCAGAAATAAGCTTTTGTTC-3'. These
primers have approximately 50 base pairs overlap with pCTCON that has been digested
from Nhe I to BanH 1. All mutagenic PCR reactions were carried out in a 100I L volume
using 10-100ng of template, 1pM primers, 0.2mM of each dNTP, 6.25U Taq (Invitrogen,
Carlsbad, CA), and 2mM MgCl,. To vary the mutation rate, both the concentration of the
analogues and the number of PCR cycles was varied. Six separate PCRs were
performed: 5 cycles with 200gtM analogues, 10 cycles with 200pM analogues, 10 cycles
with 201,M analogues, 10 cycles with 2,M analogues, 20 cycles with 20ptM analogues,
and 20 cycles with 2puM analogues. The cycling conditions used were 1 cycle of 94°C for
1 minute followed by either 5, 10 or 20 cycles of 940 C for I minute, 50°C for 1 minute,
72°C for 2 minutes, followed by 1 cycle of 72°C for 10 minutes. PCR products were gel
purified using the Gel-Extraction kit from Qiagen (Valencia, CA). After purification, a
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1:50 dilution of the 20 cycle purified PCR product and a 1:10 dilution of the 10 cycle
PCR product were prepared and 51 were used in a lOOgl PCR reaction with the
following cycling conditions: I cycle of 940C for 1 minute followed by 30 cycles of
94C for 1 minute, 50°C for 1 minute, 72°C for 2 minutes, followed by 1 cycle of 72°C
for 10 minutes. For the 5-cycle PCR purified product, the PCR was performed in the
same way except the purified template was not diluted. All amplifications were
performed using the same concentrations of reagents as in the mutagenic PCR except the
nucleotide analogies were omitted. The PCR amplified products were gel purified.
3.2.10 Construction of CDR Domain Shuffling Library of 6-22 scFv
The CDR domain shuffling libraries were prepared utilizing the homologous
recombination in yeast (Swers, et al., 2004b). First, fragments of non-immune human
scFv library were amplified using the same set of HA and c-myc primers as the
mutagenic PCR at 2.5gM. 25ng of human non-immune library DNA (7.2x 109 copies) and
0.5ptl of Tag polymerase (Invitrogen, CA) was used per PCR reaction. The reaction was
annealed at 550 C for 1 min, extended at 720C for min, and cycled for 35 times. The
900bp fragments from the PCR reaction containing the nonimmune human scFv flanked
by HA and c-myc tags were then gel purified. Meanwhile, different fragments of anti-
HAAH scFv 6-22 were prepared using primers targeting different heavy chain framework
regions and sequence downstream of the c-myc tag. 6-22 fragment missing FW to
CDR 1I was generated using primer targeting heavy chain FW2 (5'-GGATCAGGCAGTC
CCCATCGAGAGGCCTTGAGTGGCTGGG-3') and primer targeting sequence
downstream of c-myc (5'-ACAGTGGGAACAAAGTCGATTTTGTTACATCTACAC-
3'). Similarly, fragments missing FWl to CDR2 and FW1 to CDR3 were generated by
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replacing the previous FW2 primer with primers targeting FW3 (5'-CGAATAACCA
TCAACCCAGACACATCCAAGAACCAGTTCTCCC-'3) and FW4 (5'- GGGGCCAG
GGAACCCTGGTCACCGTCTCCTCAGGGAGTGCATCC-3') respectively. 10ng of
WT scFv and 2.5gM of primers were used in the reaction. The PCR reactions were
performed using Taq polymerase at an annealing temperature of 54°C for min, and at an
extension temperature of 720 C for 38sec to 65sec depending on the length of the desired
fragments. The reaction was cycled for 35 times. The CDR domain shuffling libraries
were then constructed by co-transforming the non-immune human scFv fragments,
fragments missing the desired shuffled portion (either FWI to CDRI, FWI to CDR2 or
FWI to CDR3) and a NheI-to-XhoI cut pCTCON backbone into EBY100 yeast.
3.2.11 Construction of Heavy Chain Shuffling Library of 6-22 scFv
Non-immune human heavy chain sequences were restriction digested out from the
human scFv library plasmids using NheI and BamHI, and then gel purified. Similarly, the
WT anti-HAAH scFv plasmid was digested with Nhel and BamHI to remove the WT
heavy chain., and after the digestion, the plasmid was gel purified. The non-immune
heavy chain fragments were then ligated into the digested WT backbone at a mass ratio
of 7.5 to 1. The ligated products were then electroporated into the Electro Ten-Blue®
competent cells according to the manufacturer's protocol. The plasmids were then
amplified and recovered using miniprep kit, and later electroporated into EBY 00 cells.
3.2.12 Fluorescence Activated Cell Sorting of Mutant Library
The library size of the 6-22 scFv random mutagenesis library was 3x106 and this
library was sorted six times. The 6-22 CDR domain shuffling libraries were of size 1.1 x
104, 1.2 x 104, and 1.1 x104, and were pooled together for screening. Six rounds of
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screening were performed using FACS stepping down from 500nM to 160nM of HAAH
antigen to screen for improved binders and without antigen to eliminate any binder
against the detection antibodies. The 6-22 heavy chain shuffling library was of size 1.2 x
105. Six rounds of sorting, either stepping down from 800nM to 500nM of HAAH to
screen for improved binders or without any HAAH to eliminate any binder against the
detection antibodies, were performed using FACS. The library size of the C4 scFv
random mutagenesis library was lx 10 7 and this library was sorted five times. The first
round of sorting was performed with the magnetic colloids (Miltenyi) at 50nM and then
four more rounds of FACS screening were performed to isolate improved mutants.
3.3 Results
3.3.1 Isolation of Human Antibody Fragments against HAAH
A non-immune human antibody library displayed on the surface of yeast was
sorted to isolate novel binders against HAAH (Feldhaus, et al., 2003). 1 x 109 yeast cells
were screened against biotinylated HAAH ectodomain (bio-HAAH). Two rounds of
MACS (magnetic activated cell sorting) at 300nM bio-HAAH, and then four rounds of
FACS at 300nM bio-HAAH were performed to isolate binders. Individual isolated o-bio-
HAAH binder was then labeled with unmodified full length HAAH and detected with
two previously isolated t-HAAH mouse antibodies, FB-50 and 15c7, to confirm that the
ot-bio-HAAH-I clones bind specifically to HAAH protein instead of biotinylation epitopes.
Twelve clones were confirmed to bind specifically to recombinant HAAH protein, and
their respective binding against 300nM of bio-HAAH on the surface of yeast is shown in
Figure 3.1. Sequence analysis of these twelve clones (full sequences are shown in the
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Appendix) showed that one of the binders, clone 4-6, contained only the variable region
of heavy chain with no light chain (Appendix). Surprisingly, seven of the remaining 11
binders had very similar VL sequences, but totally different VH. These light chains were
from the same family and the CDR3 of these light chains differed only at four residues,
as shown in Table 3.1. In the human library used for binder isolation, the diversity of
heavy chain is 80 fold higher than the diversity of light chain, so it is statistically rare for
a binder to have one similar light chain to pair with seven different heavy chains
(Feldhaus, el al., 2003). In addition, it was separately shown that antibody fragments
containing only the light chain of clone 6-22 (one of the seven consensus clones) was
able to bind HAAH on the surface of yeast (data not shown). Therefore, it is
hypothesized that the light chain determines the binding of these clones against HAAH,
and thus these seven clones were not functionally distinct from each other, and are likely
to bind one common epitope. Of the seven similar clones, clone 6-22 was chosen for
subsequent studies given its relatively higher affinity and expression (data not shown).
The remaining four clones (6-23, 6-24, 6-27 and 6-28), which have distinct sequences,
were also further characterized.
3.3.2 Conversion of scFv to IgG and ELISA
The (x-HAAH scFv's were reformatted for expression as IgGs. The variable
regions of the five ux-HAAH clones (6-22, 6-23, 6-24, 6-27 and 6-28) were subcloned
into a human IgGl vector containing the constant domains of the heavy and light chains.
The ligated vectors were then transiently transfected into COS-7L cells. The uX-HAAH
IgGs were secreted from the transfected COS-7L cells and purified using Protein A resin.
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Figure 3.1 Isolation of Human scFv against HAAH from Non-immune Human
Library Displayed on Yeast. Twelve clones were selected after six rounds of screening
against recombinant HAAH protein. Individual clone displayed on yeast surface was
allowed to bind 300nM of biotinylated HAAH and their binding level was detected with
FACS. Without the HAAH antigen, a single negative peak is observed. When HAAH is
present, all twelve clones have binding levels above the negative peak. These twelve
clones conceivably have different binding affinities, as their binding levels to same
concentration of HAAH are different.
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Table 3.1 Similar Light Chain Sequences for Seven out of the Twelve Isolated
HAAH Binders. The red, bold amino acid residues are the different residues among
the consensus sequences.
Clone CDR 1 CDR 2 CDR 3
6-8 SGSTSNIGRNYVYWY KLLIYRNNQRPS AAWDDSLSG-WV
6-12 SGSSSNIGNNYVYWY KLLVYRNNQRPS AAWDDSLSGRWV
6-13 SGSSSNIGSKYVYWY KLLIYRNNQRPS AAWDDSLSA-WV
6-14 SGSSSNIASNYVYWY KLLIYTNNRRPS AAWDDSLSG-WV
6-22 SGSSSNIGSNYVYWY KLLIYKNNQRPS AAWDDSLRG-YV
6-25 SGSSSNIGSNYVYWY TLLIYRNNQRPS AAWDDSLSGLYV
6-26 SGS RSNIGSNYVYWY KLLIYRNHQRPS AAWDDSLSG-YV
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Figure 3.2A shows silver staining of four of the five purified antibodies. The binding of
these five a-HAAH IgG against full length HAAH was evaluated in ELISA. Either full-
length recombinant HAAH or bovine serum albumin (BSA) was coated on the 96-wells
plate overnight and various concentrations of IgG were then incubated in each well. The
binding was detected with goat anti-human IgG-peroxidase conjugate and luminol
/peroxide solution. Figure 3.2B shows that all five IgGs have higher binding signal to
HAAH than to BSA. However, the binding of IgG 6-22 and 6-23 are significantly
stronger than the other three IgGs, even though they are at lower concentration.
3.3.3 IgG Binding against Tumor Cell Lines
HAAH expression has been observed on a variety of tumor cells. Binding of these
human a-HAAH IgGs against two HAAH-positive tumor cell lines were evaluated.
Hepatocellular carcinoma cell line, FOCUS, and lung carcinoma cell line, H460, were
used as the model cell lines. FOCUS cells and H460 cells were allowed to bind different
concentrations of a-HAAH IgGs at 40C. Binding was detected with goat anti-human IgG-
phycoerythrin conjugate and cell fluorescence was analyzed by flow cytometry. Figure
3.3A shows that compared to the non-relevant control human IgG, 6-22, 6-23, 6-24 and
6-28 IgGs all bind to both tumor cell lines. Meanwhile, no significant binding was
observed when tumor cells were labeled with 100nM of 6-27 IgG. Consistent with the
ELISA result, 6-22 and 6-23 IgGs give higher binding signals than the other IgGs, even
though they are incubated at lower concentration. This indicates that 6-22 and 6-23 IgGs
have higher binding affinity against HAAH than the other IgGs.
The apparent equilibrium binding constants (app. KD) of 6-22 and 6-23 IgGs
against FOCUS cells at 40C were determined by flow cytometry. Cells were labeled with
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Figure 3.2 Binding of Human anti-HAAH IgGs against Full-Length Recombinant
HAAH Protein. (A) Five human scFvs were reformatted into IgG. The IgGs were
secreted from the COS-7L cells and purified using Protein A resin. Four of the five
purified human IgGs were resolved in a denaturing SDS-PAGE gel, and silver staining of
the gel is shown. (B) The binding of these five human IgGs against recombinant HAAH
was evaluated in ELISA. Either full-length recombinant HAAH or bovine serum album
(BSA) was coated in the ELISA wells, and different concentration of human IgG was
allowed to bind in each well. IgG 6-22 and 6-23 show higher binding toward HAAH even
though they are at lower concentrations than the other 3 human IgGs (6-24, 6-27 and 6-
28). There is minimal binding of these human IgGs to BSA. Error bars in HAAH binding
are result of triplicate trials.
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Figure 3.3 Binding of Human anti-HAAH IgG Against Tumor Cell Lines. (A)
Different concentrations of human IgG were allowed to bind two tumor cell lines,
FOCUS and H460. Their bindings were detected with FACS and their mean fluorescence
units (MFU) are shown. At 5nM, both 6-22 and 6-23 IgGs gave significant binding to
both tumor cell lines. IgG 6-24 and 6-28 bind the tumor cells only at high concentrations
(50 to 100nM), while 6-27 IgG did not show any significant binding to the tumor cells.
(B) The binding affinities of 6-22 and 6-23 IgG against FOCUS cells were then
determined. Triplicate trials were performed. The apparent dissociation constants of 6-22
(open symbols) and 6-23 IgGs (dark, closed symbols) were determined to be 1.0 ± 0.2nM
and 20 ± 1 OnM respectively.
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different concentrations of IgGs, and then the binding was detected with goat anti-human
IgG-phycoerythrin conjugate. Triplicate trials were performed for each IgG. Figure 3.3B
shows that the app. KD of 6-22 and 6-23 IgGs was determined to be 1.0 ± 0.2nM and 20 +
10nM respectively.
3.3.4 Domain Mapping of Clone 6-22 and 6-23
The respective binding domain of clone 6-22 and 6-23 were studied to determine
whether they bind the catalytic domain of HAAH. Recombinant catalytic domain of
HAAH was coated on the ELISA wells, then different IgGs were allowed to bind in each
well. IgG 6-28, which did not display significant binding to full-length HAAH at 300nM
(Figure 3.2B), was used as a human IgGl isotype (negative) control. Figure 3.4A shows
that 6-22 IgG gives significant binding to the catalytic domain of HAAH, while 6-23 IgG
has minimal binding to the catalytic domain compared with 6-28 IgG. This indicates that
6-22 IgG binds the catalytic domain of HAAH, while 6-23 IgG binds the charged non-
catalytic domain of HAAH, which along with the catalytic domain, was expressed on the
surface of plasma membrane in tumor cells.
Although 6-22 IgG and 6-23 IgG bind different domains of HAAH, it is still
conceivable that their binding epitopes are overlapping. To this end, we investigated
whether the antibodies compete with each other on tumor cell binding. FOCUS cells were
incubated simultaneously with Alexa-488-labeled 6-22 IgG (A488-6-22) and different
concentrations of unlabeled 6-22, 6-23 and non-relevant control human antibody. Figure
3.4B shows that the binding of A488-6-22 is competed off with increasing concentration
of unlabeled 6-22 IgG. However, the binding signal is not affected with the addition of
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Figure 3.4 Domain Mapping of 6-22 and 6-23 IgG. (A) Binding of 6-22 and 6-23 IgGs
to the catalytic domain of HAAH was evaluated in ELISA. Recombinant catalytic
domain of HAAH was coated in ELISA cells, and IgG was allowed to bind in each well.
6-28 IgG, which show very weak binding to full-length HAAH in Figure 3.2B, was used
as an isotype control. Results showed that 6-22 IgG showed strong binding to the
catalytic domain of HAAH, while 6-23 IgG did not bind the catalytic domain. (B)
Competition experiment was set up to determine if 6-22 and 6-23 bind overlapping
epitopes. Alexa-488 labeled 6-22 IgG and different concentrations of unlabeled 6-22, 6-
23 and non-relevant human control IgG were co-incubated with H460 cells. The binding
level was detected with FACS. Results indicated that the fluorescence of Alexa-488
labeled 6-22 IgG was not competed off with increasing concentration of 6-23 IgG,
demonstrating that 6-22 and 6-23 bind non-overlapping epitopes.
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excess unlabeled 6-23 or control IgGs, indicating that neither IgG competes with 6-22
IgG on binding tumor cells. Unpublished work also illustrates that neither 6-22 nor 6-23
IgG competes with the mouse antibodies FB-50 and 15c7. Overall, 6-22 IgG and 6-23
IgG are two human antibodies targeting different epitopes of HAAH. Since 6-22 IgG has
higher affinity and targets the catalytic domain of HAAH, it is further characterized.
3.3.5 Immunohistochemistry using 6-22 IgG
Paraffin-embedded tissue sections of pancreatic adenocarcinoma and adjacent
chronic pancreatitis from the same patient were immunostained with 6-22 IgG.
Immunoreactivity was revealed by the goat-anti human IgG-peroxide conjugate. HAAH
expression in these pancreatic adenocarcinoma tissues was previously confirmed by a
positive IHC stain using mouse antibody FB-50 (data not shown). Figure 3.5 shows the
staining of both tumorous and adjacent non-tumorous tissues using 6-22 IgG. There is
intense staining on the ductal areas of pancreatic adenocarcinoma using 6-22 IgG, while
there is minimal staining on the ducts of adjacent pancreatitis tissues. Results here
indicate that 6-22 IgG targets the HAAH-expressing tissues specifically, with minimal
non-specificity against the non-tumorous tissues.
3.3.6 Internalization of 6-22 IgG into the Tumor Cells
The internalization ability of the 6-22 IgG into tumor cells was studied. Alexa-
488 labeled 6-22 IgG was incubated with the FOCUS cells at either 40C or 370C for 4 hr.
The fluorescence of the cells was imaged by deconvolution microscopy. Figure 3.6A
shows that incubating at 4C, A488-6-22, which is denoted by the green fluorescence,
primarily resides on the outer membrane of the cells. However, when incubated at 370C,
6-22 IgG distributes throughout the inside of the cells, indicating extensive internalization
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Figure 3.5 Immunohistochemistry Staining of Human Tissue using 6-22 IgG.
Paraffin-embedded tissue sections of pancreatic adenocarcinoma and adjacent chronic
pancreatitis were immunostained with 6-22 IgG. Immunoreactivity was revealed by the
goat-anti human IgG-peroxide conjugate and DAB stain. There is intense staining of the
ductal area of pancreatic adenocarcinoma using 6-22 IgG, while there is minimal staining
on the duct of adjacent pancreatitis tissue.
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of 6-22 IgG into the FOCUS cells. Similarly, internalization of 6-22 IgG was also
observed on H460 cells, as shown in Figure 3.7.
Internalization kinetics was investigated. First, a pulse-chase experiment was
performed to probe the recycling of 6-22 IgG (Austin, et al., 2004). After a 3hr
internalization pulse of A488-6-22, FOCUS cells were surface-quenched on ice with
rabbit anti-Alexa 488 IgG, and then returned to 370 C incubation under the continuous
presence of quenching antibody. At various times, cells were detached, surface-quenched
on ice and then fluorescence inside the cells was analyzed by a flow cytometer. Figure
3.6B shows that cell fluorescence stays about the same within the 5hr chase period,
indicating that fluorescence quenching was negligible. Thus, there was minimal amount
of antibody recycling within the 5hr chase period.
Next, the internalization rate of 6-22 IgG was estimated. FOCUS cells were
incubated at 370 C with either non-saturating concentrations of A488-6-22 or Alexa-488
control IgG; both IgGs have the same number of Alexa-488 molecules per IgG. At
various times, cells were detached and fluorescence inside the cells was detected by flow
cytometry. Figure 3.6C shows that A488-6-22 and Alexa-488 control IgG are taken up at
a rate of 22.2 and 3.0MFU/hr respectively by the tumor cells. The uptake of the Alexa
control IgG represents the solution phase (non-specific) uptake of fluorescent molecule in
solution, which accounts for about 14% of A488-6-22 uptake rate in this case. When the
cells were labeled with the incubating concentration of A488-6-22 on ice, the minus-
background MFU was about 15 (data not shown). Accounting for solution phase uptake
and minimal antibody recycling, an average internalization time of approximately 45min
is calculated.
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Figure 3.6 Internalization of 6-22 IgG into FOCUS cells. (A) Alexa-488 labeled 6-22
IgG was incubated with FOCUS cells at 40C or 37°C for 4hr. Cells were then imaged
using a deconvolution microscope. At 40 C, antibody mainly resided on the outside of the
cells, while at 37°C antibody was internalized into the cells, illustrated by the green
fluorescence inside the cell. The blue color indicated the Hoechst stain of the nuclei. (B)
A pulse and chase experiment was set up to show that the fluorescence inside the cells
stayed about constant within the 5hr of chase period (see material anrid methods).
Therefore, there was minimal recycling of the antibody back to the surface. (C) The
internalization rate of Alexa-488 labeled 6-22 IgG was investigated. A488-6-22 or
control antibody was incubated with FOCUS cells at 37°C and at various times,
fluorescence inside the cells was detected with FACS. Results indicated that the rise of
fluorescence was 22.2MFU/hr and 3.0MFU/hr respectively for A488-6-22 and control
antibody.
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Figure 3.7 Internalization of 6-22 IgG into H460 cells. Alexa-488 labeled 6-22 IgG or
control Alexa labeled IgG was incubated with H460 cells at 370C for 24hr. Cells were
trypsinized and fluorescence of the cells was analyzed using a flow cytometer.
Trypsinized cells were also stained with Hoechst dye, allowed to settle on lysine-coated
slides and then imaged using a deconvolution microscope. Cells that were incubated with
Alexa-488 6-22 IgG have significant higher fluorescence than the cells incubated with
control IgG. Microscopic study shows that the green fluorescence in the Alexa 488-6-22
IgG treated cells is from the inside of the cells. This indicates that 6-22 IgG is
internalized into the H460 cells.
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3.3.7 Cytotoxicity of 6-22 IgG Immunotoxin on Tumor Cell Lines
The capability of 6-22 IgG to serve as a targeting domain in immunotoxin therapy
was tested. The toxin used in this study was saporin, a ribosome-inhibiting plant toxin.
Commercially available secondary antibody-conjugate, goat-anti-human IgG-saporin
conjugate (Hum-ZAP, H-Z), allows facile assessment of the potential immunoconjugate
efficacy. H-Z binds primary human targeting antibody, and then through the
internalization of primary antibody is delivered intracellularly to inhibit cellular
proliferation. In our study, 6-22 IgG or non-relevant human control antibody was pre-
incubated with H-Z and then the complex was presented to the FOCUS cells. In-vitro cell
viability was determined after three days of incubation. Figure 3.8 shows that neither
10nM of 6-22 IgG nor 22nM of H-Z alone inhibits cell growth. In addition, there was no
observable cytotoxicity when the complex of control human antibody and H-Z was
presented to the cells. However, the viability of the 6-22/H-Z treated cells was lowered
by about 30%, indicating that 6-22 IgG was able to specifically facilitate the
internalization of the toxins. Similarly, increased cytotoxicity was also observed when 6-
22/H-Z was used to treat H460 cells; however the extent of immunotoxin efficacy on
H460 was not as high as on FOCUS, as H-Z alone had higher background toxicity to the
H460 cells (Figure 3.8). Overall, results here suggest that 6-22 IgG can be employed as a
targeting domain for conjugating immunotherapy for HAAH-expressing tumor cells.
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Figure 3.8 C'ytotoxicity of 6-22 Immunotoxins on FOCUS and H460 Cells. Efficacy
of using 6-22 IgG as the targeting module in immunotoxin was evaluated. 6-22 IgG or
control human IgG was pre-incubated with H-Z (goat anti-human IgG-saporin
conjugate). FOCUS or H460 cells were then exposed to the IgG alone, H-Z alone or the
pre-incubated complexes. Viability of the cells was determined after 3 days of incubation.
Results showed that 6-22 IgG alone did not have any cytotoxicity toward the tumor cells.
For FOCUS cells, complex of 6-22 IgG/H-Z inhibits cell growth. However, the inhibition
of H460 cell growth from 6-22IgG/H-Z complex is not as significant as for FOCUS cells.C it,1IVLIVILV- L VIYV~IVIV VVblllUI VII VVVIV
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3.3.8 Random Mutagenesis of 6-22 scFv
Three different mutagenesis strategies were directly compared for affinity
maturation of 6-22 scFv: error-prone PCR (random mutagenesis), CDR shuffling
(Figures 3.9A-C), and heavy chain shuffling (Figure 3.9D). Seven higher affinity clones
isolated from the error-prone PCR mutagenized library were sequenced and found to
possess a strikingly high average of 25 + 16 mutations, significantly higher than the
number of mutations in the unscreened library (6.6 + 8.0 for 17 unselected clones;
difference statistically significant with p < 0.001). The dissociation constant of the best-
improved clone (1 lml-2) was determined to be 120 ± 20nM, a two order of magnitude
improvement (Figure 3.10). Upon closer examination of the amino acid sequences of
these improved clones, cysteine deletion or insertion in the VH domain was frequently
observed. Five of the seven sequenced clones replaced the VH22 cysteine residue with
either arginine or tyrosine, abolishing the VH intra-domain disulfide bond. Of these five
clones, three have mutations introducing a novel cysteine in either the heavy chain FW3
or light chain CDR3. For the two clones that did not alter VHCys22, one clone did not
introduce a new cysteine, but had 19 amino acid changes. The other clone had 51 amino
acid mutations, and also replaces a tyrosine with a cysteine in the heavy chain CDR3
loop, just four residues away from the consensus VH22 cysteine. The frequent cysteine
mutations and extraordinarily high number of mutations in the selected clones suggest
that fairly dramatic structural change in the heavy chain architecture is required to
improve the affinity of this clone's starting binding motif. The starting scFv has
respectively zero and four mutations from germline heavy and light chain framework
sequences. The clones isolated from the random mutagenesis studies have germline
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Non-immune library 6-22 scFv fragments
6-22 VL
A
VH from human library BamH
Figure 3.9 Schematic of CDR Domain and Heavy Chain Shuffling Mutagenesis
Methods. CDR domain shuffling (A-C) employs in vivo homologous recombination in
yeast, while heavy chain shuffling (D) employs ligation of heavy chain fragments into
restriction digested 6-22 backbone. (A) 6-22 VHFW1 and VHCDR1 are exchanged with
the non-immune library fragments. (B) 6-22 VHFWI, VHCDR1, VHFW2, and VHCDR2
are exchanged. (C) 6-22 VHFW to VHCDR3 are exchanged. (D) Heavy chain fragments
from non-immune human library are paired with the 6-22 light chain.
82
(A)
(B)
(C)
(D)
framework mutations ranging from 8 to 35, which would raise substantial concerns about
immunogenicity in any potential therapeutic application of this antibody.
3.3.9 CDR Domain Shuffling of 6-22 scFv
A CDR domain shuffling library was constructed by replacing either heavy chain
FWl to CDR , FW1 to CDR2, or FWl to CDR3 of the WT scFv with the non-immune
heavy chain fragments (Figures 3.9A-C) respectively (Swers, et al., 2004), with all three
pooled into a single library for screening. After sorting, four unique affinity-improved
clones were isolated, of which three had replaced FWI to CDR3 with a sequence from
the nonimmune library, (effectively a full VH chain shuffling event), and the remaining
clone replaced the FW1 to CDR2 sequence. Sequences of the clones are shown in the
Appendix. As shown in Figure 3.10, the dissociation constant of this CDR (FW to
CDR2) shuffled mutant (C4) was 17 + 5nM, 3 order of magnitude improvement relative
to the WT affinity, and one order of magnitude improvement over the random
mutagenesis clone. This CDR shuffled mutant possesses only two mutations from the
germline heavy chain framework sequence, significantly fewer than in the random
mutagenesis clones.
3.3.10 Heavy Chain Shuffling of 6-22 scFv
A heavy chain shuffling library was constructed by shuffling heavy chains from
the nonimmune library against the WT light chain. (Figure 3.9D). Five clones from the
unscreened library were sequenced and confirmed to have unique heavy chains (data not
shown). Following six rounds of sorting, eleven clones were identified with unique heavy
chains distinct from the initial scFv. Sequences of the clones are shown in the Appendix.
The dissociation constants for two selected clones, LLml I and LLml 3, were determined
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Figure 3.10 Topology and Affinities of 6-22 WT scFv and Mutants Isolated from
Different Mutagenesis Strategies. The KD was determined on the yeast surface using
recombinant full-length HAAH protein. The KD of the clone isolated from random
mutagenesis was two orders of magnitude lower than the KD of WT. Meanwhile, the
clones isolated from CDR shuffling and heavy chain shuffling libraries have three orders
of magnitude improvements in binding affinity over the WT scFv.
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to be 16 4nM and 26 8nM respectively (Figure 3.10), a three order of magnitude
improvement in affinity over the starting scFv. The extent of the affinity improvement in
this heavy chain shuffling library was one order of magnitude higher than the extent of
the affinity improvement in the random mutagenesis study, although the library sizes
were 25 fold smaller than the random mutagenesis library. The affinities of these chain-
shuffled mutants are comparable to the affinity of the CDR-shuffled mutant (C4). Similar
to the CDR-shuffled mutants, these clones also have minimal deviation from the heavy
chain germline framework sequence (on average 4 + 2 mutations).
3.3.11 Conversion of C4 scFv to C4 IgG
CDR shuffled mutant C4 scFv, which has the same heavy chain CDR3 and light
chain as 6-22 scFv, was reformatted as IgG. The binding affinities of C4 IgG on two
FOCUS and H460 cells were determined and compared with the binding affinities of
wild-type 6-22 IgG. Figure 3.11 shows that the binding affinities of C4 IgG are similar to
those of 6-22 IgG on two different cell lines, indicating that the extent of affinity
improvement on IgG level is not as significant as those of scFv format.
3.3.12 Random Mutagenesis of C4 scFv
C4 scFv was further affinity matured using random mutagenesis. A library of
lx107 mutants was constructed, and five rounds of screening were performed to isolate
improved mutants. Two mutants (C4-8 and C4-18) that have higher ratio of binding-to-
display signal than C4 scFv were isolated. The affinity of C4-8 was not determined, and
its sequence is shown in the Appendix. The dissociation constant of C4-18 was
determined to be 0.6 + 0.1nM on yeast surface, which is two order of magnitude
improvement over the C4 scFv (Figure 3.12). The nuclei acid and amino acid sequences
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Figure 3.11 Affinity Comparison of 6-22 and C4 IgGs against FOCUS and H460
Cells. C4 sc-Fv was reformatted as IgG. 6-22 and C4 IgGs were then titrated against
tumor cell lines, FOCUS and H460. Results show that the affinities of 6-22 and C4 IgGs
are similar on both tumor cell lines.
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1 caggtacagctgcagcagtcaggtccaggactggtgaagccctcaccgaccctctcactc 60
T C A I S G D S V S S N S A A W N W V R
61 acctgtgccatctccggggacagtgtctctagcaacagtgctgcttggaactgggtcagg 120
Q S S R G L E W L G R T Y Y R S K W Y
121 cagtccctatcgagaggccttgagtggctgggaaggacatactacaggtccaagtggtat 180
N G Y A V S V M E R I T N D T S R N
181 aatggttatgcagtatctgtgaggggtcgaataaccaccaacgcggacacatccaggaac 240
Q F S L Q L N S V T P E D T A V Y Y C A
241 cagtt ctccctgcagctgaactctgtgactcccgaggacacggctgtgtattactgtgca 300
R T G Y S S S W V V N S N Y W G Q G T L
301 aggaccgggtatagcagtagctgggtcgtaaattctaactactggggccagggaaccctg 360
V T V S S G S A S A P T G I L G S G G G
361 gtcaccgtctcctcagggagtgcatccgccccaaccggaattctagggtccggtggcggt 420
G S G G G G S G G G G S Q P A L T Q S P
421 ggcagcggcggtggtggttccggaggcggcggttctcagcctgcgctgactcagtcaccc 480
S A S G T P G Q R V T I S C S G S S S N
481 tcagcgtctgggacccccgggcagagggtcaccatctcttgttctggaagcagctccaac 540
I G S N Y V Y W Y Q Q L P G T A P K L L
541 atcggaagtaattatgtatactggtaccagcagctcccaggaacggcccccaaactcctc 600
I Y K N N Q R P S G V P G R F S G S K S
601 atctataagaataatcagcggccctcaggggtccctggccgattctctggctccaagtct 660
G T A A S L A I S G L R S K D E A D Y Y
661 ggcaccgcagcctccctggccatcagtgggctccggtctaaggatgaggctgattattac 720
C A A W D D S L R G Y V F G T G T K L T
721 tgtgcagcatgggatgacagcctgcgtggttatgtcttcggaactgggaccaagctgacc 780
V L
781 gtccta 786
Figure 3.12 The Affinity and Sequences of C4-18 scFv. (A) The affinity of C4-18 scFv
was determined on the yeast surface. The KD was determined to be 0.6nM, 2 order of
magnitude improvement over C4 scFv (17nM). (B) The nucleic acid and amino acid
sequences of C4-18 scFv. The CDRs are underlined. The difference between C4-18 and
6-22 sequences are highlighted in green (acquired from the CDR domain shuffling of 6-
22) and yellow (acquired from the random mutagenesis of C4).
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of C4-18 is also shown in Figure 3.12. Compared with the amino acid sequence of 6-
22scFv, C4-18 has 15 mutations and five of the 15 mutations occur in the CDRs.
Meanwhile, C4-18 has 11 mutations from C4, and three of the 11 mutations are located at
the CDRs.
3.4 Discussion
In this study, novel human antibodies against human aspartyl (asparaginyl) f-
hydroxylase were isolated from a non-immune human antibody library using yeast
surface display. These antibodies have been shown to bind specifically to tumor cell
lines and tumor tissues, while they have minimal activity against normal tissue. Two of
the higher affinity IgGs, 6-22 and 6-23, were shown to bind different epitopes on HAAH.
6-22 IgG was also shown to internalize into the tumor cells, and able to deliver toxins
into the tumor cells. Moreover, 6-22 scFv was affinity-matured using different
mutagenesis methods, and the binding affinity of an isolated improved mutant (C4-18)
had five order of magnitude improvements over the wild-type 6-22 scFv. Overall, these
human -HAAH antibodies may be useful for targeting a variety of HAAH-expressing
tumor cells, and they are also candidates for conjugating toxins, enzymes, radionuclides,
liposomes or virus for targeted immunotherapy.
Human -HAAH antibodies with a range of affinities were isolated in our study.
The apparent dissociation constants of the IgG-reformatted clones range from about
micromolar for 6-28 IgG to about single digit nanomolar for 6-22 IgG. The scFv format
of 6-22 has a binding affinity of about 80nM against both FOCUS and H460 cells (data
not shown). Previously, antibodies against protein antigens were isolated from this non-
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immune library and the binding affinities of the isolated protein binders ranged from
single digit nanomolar to around micromolar (Feldhaus, et al., 2003). Other studies using
phage non-immune human antibody libraries have also selected protein-binding leads
ranging from 0.2nM to micromolar (de Haard, et al., 1999; Griffiths, et al., 1994; Hoet, et
al., 2005; Knappik, et al., 2000; Marks, et al., 1991; Sheets, et al., 1998; Soderlind, et al.,
2000; Vaughan, et al., 1996). Therefore, the affinities of the clones isolated against
HAAH in this study are in accordance with those isolated from other non-immune human
libraries. However, it is not certain beforehand that high affinity anti-HAAH clone can
be directly isolated from a non-immune human library, as HAAH is a self-antigen. Such
self-reactive clones may be deleted from the non-immune repertoire, which was used to
construct our human antibody library. Usually, if such a weak lead is the only available
clone, lengthy in-vitro affinity maturation probably is required to substantially improve
the binding affinity of antibody (Pancook, et al., 2001). One advantage of isolating self-
antigen binder from in-vitro human library is that in-vitro random pairing of VH and VL
in the library construction generates greater antibody diversity. This may be in the case of
clone 6-22; the light chain of 6-22 is very similar to the light chains of other clones and
can bind the antigen weakly by itself. Pairing of different heavy chains with this similar
light chain result in binders with different affinity, as shown in the differential binding
signals in the selected clones (Figure 3.1 and Table 3.1). The pairing of 6-22 heavy chain
with this consensus light chain appears to give the highest binding affinity. In-vitro
affinity maturation involving shuffling heavy chain against this consensus light chain
may further explore the possibility of different heavy chain pairing, hence improving the
affinity of this particular clone (Marks, et al., 1992).
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The affinities of FDA-approved antibodies range from 0.lnM to lOnM
(Cardarelli, et al., 2002; Goldstein, et al., 1995; Spiridon, et al., 2002). The apparent KD
of 6-22 IgG is about InM, and within the affinity range for marketed antibodies. The
reformatting of 6-22 scFv to IgG increases its affinity from 80nM to about nM.
Therefore, it may be advantageous to reformat antibody fragment that directly isolated
from the non-immune library to avoid lengthy affinity maturation. It was previously
shown in the work of Nielsen and co-workers (Nielsen, et al., 2000) that reformatting the
monovalent antibody fragments to bivalent formats when they were in lower affinity had
greater benefit in apparent KD improvement. They showed that reformatting three scFvs
against ErbB2 with affinities of 360nM, 70nM and 3nM to diabodies resulted in affinity
improvements of 65, 19 and 7.7 folds respectively. Similar apparent affinity
improvement was also seen in reformatting a Fab against tumor-associated MUCI into
IgG (Henderikx, et al., 2002). However, if monovalent antibody fragment is desired for
tumor penetration or targeting, in-vitro affinity maturation process can be carried out on
the monovalent fragment of 6-22 to improve its affinity.
HAAH expression has been detected on the surfaces of numerous cancer cell
types. In our study, the human a-HAAH IgGs did not show any significant anti-
proliferation effect in-vitro (Figure 3.8), however it does not preclude the therapeutic use
of a-HAAH antibodies in vivo. It was previously shown in some of the FDA-approved
antibodies that the effector function of immune system triggered by the antibodies played
an important, if not major, role in tumor reduction in vivo. Di Gaetano and co-worker's
study on complement activation showed that tumor xenografts lacking the first
component of the classical complement pathway were not protected from Rituxan (Di
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Gaetano, et al., 2003). They concluded that complement activation was fundamental for
the in vivo therapeutic effect of Rituxan. In addition, two separate studies both showed
that polymorphism in Fc gamma receptor IIIa (FCGR3A) was associated with the
therapeutic effect of Rituxan in patients (Cartron, et al., 2002; Dall'Ozzo, et al., 2004). A
significant difference in objective response rate was observed for the FCGR3A-158V
homozygous patients and FCGR3A-158F carriers patients (response rate of 90% vs. 51%
after lyear) (Cartron, et al., 2002). The observed difference was due to more efficient
antibody-dependent cell-mediated cytotoxicity (ADCC) against the CD20+ cells
(Dall'Ozzo, et al., 2004). Other studies also showed that the Fc receptor on human
antibody and its interactions with effector cells were important for the therapeutic effect
of both Rituxan and Herceptin in vivo (Clynes, et al., 2000). In addition, Spiridon and co-
worker compared the in vitro and in vivo activities of anti-HER-2 IgG and F(ab') 2
(Spiridon, et al., 2004). They found out that even though the in vitro anti-proliferation
and proapoptotic effects of the IgG and F(ab')2 were similar, their therapeutic effects in
vivo were dramatically different. In vivo studies showed that IgG, which can mediate
ADCC and complement dependent cytotoxicity, exhibited significant antitumor activity,
while their F(ab') 2 fragments were only marginally effective. These studies in general
show that in vivo activities of Herceptin and Rituxan are largely Fc dependent, although
both antibodies have in vitro anti-proliferation effects. Additional studies indicated that
even targeting a biologically inactive tumor antigen like Ep-CAM with human antibodies
was also able to trigger ADCC both in vitro and in vivo (Naundorf, et al., 2002; Prang, et
al., 2005). Therefore, perhaps simply targeting tumor cell surface antigens with human
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antibodies in vivo can elicit therapeutic effect by activating the effector function of the
immune system.
Different options of tumor therapy targeting the HAAH have been explored in
previous studies. Antisense oligodeoxynucleotides (ODN) targeting HAAH mRNA was
used to inhibit HAAH expression in tumor cells (Ho, et al., 2002; Maeda, et al., 2003).
Maeda et al. showed that transfecting the cholangiocarcinoma cells with antisense ODN
was able to substantially reduce the motility of the tumor cells in vitro (Maeda, et al.,
2003). Ho and co-workers also developed a set of antisense oligonucleotides to regulate
the expression of HAAH and humbug. They used an antisense oligonucleotide that
inhibited the expression of both HAAH and humbug in vitro to target lung tumor cells in
nude mice. Their results showed that the antisense oligo had poor penetration into the
tumor cells. Even though there was modest effect on tumor growth in vivo, the expression
of HAAH transcript in antisense-treated group was unaltered comparing with the control
group. In general, antisense therapy was developed to inhibit HAAH expression in vitro,
however their usages in vivo is still being hampered by issues such as stability and
binding specificity. On the other hand, antibody therapy has the advantage of targeting
tumor cells specifically. In our study, in addition to targeting the tumor cells, 6-22 IgG
was shown to internalize into the tumor cells. The internalization time is about 45min,
which is similar to the time of constitutive membrane turnover (Thilo, 1985). Thus, there
may not be any active mechanism involved in the internalization of the HAAH/6-22 IgG
bound complex. Moreover, our recycling experiment, modified from the work of Austin
and co-workers (Austin, et al., 2004), shows that once internalized 6-22 IgG is not
recycled back to the surface within the incubation time. This is different from both
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Herceptin and transferrin, which were shown to rapidly recycle (Austin, et al., 2004). In
general, utilizing the internalization ability of the antibody, toxins, liposome and viruses
can be conjugated to 6-22 IgG for targeted therapy. Different protein toxins including
Pseudomonas exotoxin, Diphtheria toxin, gelonin, ricin A chain, as well as small
molecule toxins such as maytansinoids and caliecheamycins have been either chemically
conjugated or genetically fused to different antibodies to construct immunotoxins and
immunochemotherapeutics (Bera, et al., 1999; Hexham, et al., 2001; Ma, et al., 2001;
Rosenblum, et al., 2003; Safavy, et al., 2003; Thompson, et al., 2001). In our work, a
commercially available secondary antibody-saporin conjugates (H-Z) was used. Our
study shows that 6-22 IgG can facilitate the internalization of saporin, hence eliciting
cytotoxicity to the tumor cells in vitro. The work here is a proof of concept that 6-22 IgG
can be used as a targeting module for delivering toxins and other moieties into the cells.
For future clinical or animal study, the choice of toxins and the conjugating methods will
need further consideration and optimization.
For the engineering of 6-22 scFv, affinity improvement by error prone PCR
mutagenesis required extremely high substitution rates, and the structurally important
cysteine (H22) in the heavy chain was frequently mutated, implying that small changes in
structure or CDR were insufficient to improve the complementary of interaction with the
antigen. This high level of deviation from germline framework sequence in the isolated
mutants could very well create immunogenic epitopes, and consequently in the absence
of an alternative mutagenesis strategy this antibody lineage would be unlikely to be
developed further. In contrast, recombinational mutagenesis (CDR shuffling and heavy
chain shuffling mutagenesis) generated mutants with substantial changes from the WT
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sequence while conserving the germline framework sequence in the mutants.
Recombinational mutagenesis is much more preferable in this case as the isolated
mutants have the higher affinity improvement (3 order of magnitude) but far fewer
framework mutations. In cases such as this, it is favorable to use recombinational
mutagenesis over somatic hypermutation to generate improved mutants with substantial
changes from the first generation antibody, while keeping the sequence similar to the
germline framework sequence.
In summary, novel human antibodies targeting HAAH have been isolated. These
antibodies have been shown to bind specifically to the HAAH-expressing tumor cells.
One of the antibodies, 6-22 IgG, was also shown to internalize into the tumor cells and
facilitate the internalization of toxins. The scFv format of 6-22 was also engineered to
0.6nM in two rounds of mutagenesis (CDR domain shuffling and random mutagenesis).
These a-HAAH IgG and scFv can potentially be used in the diagnosis and therapeutic
treatments of HAAH-expressing tumor cells.
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Chapter 4: Quantitative Screening of Yeast Surface-Displayed
Polypeptide Libraries by Magnetic Bead Capture
4.1 Introduction
Directed evolution is the most effective method currently available for exploration
and engineering of new protein functions and properties. Directed evolution involves
displaying a diverse array of protein mutants on a scaffold (Shusta, et al., 1999), and
favorable mutants are selected or screened from the pool. Such scaffolds include
bacteriophage (Griffiths and Duncan, 1998; McCafferty, et al., 1990; Smith, 1985;
Wilson and Finlay, 1998), Escherichia coli (Georgiou, et al., 1997; Griffiths and Duncan,
1998)and Saccharomyces cerevisiae (Boder and Wittrup, 1997).
Appropriate quantitative selection or screening methodologies for polypeptide
libraries are critical for successful recovery of favorable mutants. Different
methodologies exist for different display systems. For example, phage libraries are
typically screened by immobilized ligand, such as panning and affinity columns (Marks,
et al., 1991). To avoid avidity artifacts in panning, phage library screening is also
performed with biotinylated ligand and streptavidin-coated paramagnetic beads
(Griffiths, et al., 1994; Hawkins, et al., 1993; Hawkins, et al., 1992). Meanwhile, flow
cytometric analysis with fluorescent probe labeling has been used to screen for improved
mutants from cell surface-displayed combinatorial libraries (Boder, et al., 2000;
Christmann, et al., 1999; Daugherty, et al., 1998; Daugherty, et al., 2000b; Francisco, et
al., 1993; Kieke, et al., 1999; Wentzel, et al., 1999). Flow cytometric analysis has the
advantages of being a reliable, and quantitative high-throughput screening method for
95
libraries of 108 cells. However, many laboratories do not have ready access to flow
cytometers, somewhat restricting the use of cell-based libraries for protein engineering.
In addition to the availability issue, sorting a library greater than 1010 clones by
cytometer would be time-consuming. Commercially available flow cytometers are
capable of sorting cells at a rate 107 to 108 cells/hr, with state-of-the-art machines sorting
at about 4 x 108 cells/hr (Ashcroft and Lopez, 2000). To sort a library of 10 °0 clones, flow
cytometric analysis would require about one day of sorting time. Example of such a large
library is naive human antibody library. An initial library of I x 1010 clones may be
required to obtain antibodies with affinities in the nanomolar range (Griffiths and
Duncan, 1998). To reduce both initial library size and sorting time, magnetic cell sorting
has been employed to pre-enrich target cells from a library greater than 108 cells prior to
flow cytometric screening(Christmann, et al., 1999; Wentzel, et al., 1999). Magnetic
separation is convenient, simple, fast and has been utilized in many applications for cell
isolation(Chalmers, et al., 1998; Safarik and Safarikova, 1999). However, the
quantitative enrichment capabilities of magnetic bead capture have not been
demonstrated previously. Therefore, we have used model antibody systems to test the
feasibility of magnetic bead separation as an alternative, quantitative screening tool for
cell-based polypeptide library screening.
The model antibodies used for most of the studies were anti-fluorescein
antibodies (an antibody/hapten system). 4-4-20 is an anti-fluorescein antibody with KD of
0.7+0.3nM (in PBS). The single chain Fv (scFv) fragment of 4-4-20 was expressed on
the yeast surface as described previously (Boder, et al., 2000). Higher affinity scFv
mutants, namely 4M2.5, 4M3.6 and 4M3.7, which were previously isolated by screening
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randomly mutagenized libraries of yeast surface-displayed anti-fluorescein scFv (Boder,
et al., 2000), were also displayed on yeast and employed in this study, along with the 4-4-
20 scFv. Different ratios of 4-4-20-displaying cells to cells displaying no scFv were
mixed, incubated with biotinylated antigen and then captured by streptavidin-coated
magnetic beads. This method was used to capture 4-4-20 displaying cells (binders) from
an excess of non-displaying cells (nonbinders). The ability to isolate binders from
nonbinders by magnetic bead capture was further explored in an antibody/protein system,
D1.3 scFv / hen egg lysozyme. Furthermore, a kinetic screen for slower dissociation was
performed to enrich 4M3.6-displaying cells from an excess of 4M2.5-displaying cells
(7.7-fold lower in dissociation rate than 4M3.6). The effects of shear on the enrichments
of favorable mutant by magnetic bead capture in binder identification and kinetic
screening cases were also determined. The abilities of magnetic beads to both
quantitatively isolate binders in an excess of non-binders, and isolate improved mutants
in a kinetic screen for slower dissociation were assessed.
4.2 Materials and Methods
4.2.1 Yeast Strains and Plasmids
The yeast strain used in this study was EBYlO00 (Boder and Wittrup, 1997). Four
display plasmids containing different anti-fluorescein single chain Fv (scFv) fragments
genes: pCT302 (4-4-20, wild-type), pCT4M2.5, pCT4M3.6 and pCT4M3.7 were
previously prepared (Boder, et al., 2000). The pCT201-D1.3, an anti-hen egg lysozyme
D1.3 scFv displaying plasmid, was also previously prepared (VanAntwerp and Wittrup,
2000). Each of the plasmids previously described contained a Trp marker and was
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transcribed for a single copy of scFv per display unit (a disulfide-bonded Agal and Aga2
yeast cell wall proteins) (Boder and Wittrup, 1997). A standard pRS315 CEN shuttle
vector providing the LEU2 marker was used for the differentiation of different scFv
displaying cells on selective media (Sikorski and Hieter, 1989). Plasmids were
transformed into yeast (EBY100) using Frozen EZ Yeast Transformation IITM (ZYMO
Research, Orange, CA).
4.2.2 Materials and Media
2.8gm-diameter streptavidin-labeled paramagnetic beads (Dynabead® M-280
streptavidin, magnetic mass susceptibility of 100 ± 25x10-6 m3/kg) were obtained from
Dynal (Lake Success, NY). Antigens including fluorescein-biotin, and hen egg lysozyme
(HEL) were purchased from Sigma (St. Louis, MO). HEL was biotinylated using the
FluoReporter Protein Labeling Kits (Molecular Probes, Eugene, OR). Streptavidin-
phycoerythrin (PharMingen, San Diego, CA) was used as labeling reagents. The buffer
used was phosphate-buffered saline (PBS) with 0.1% bovine serum albumin (BSA)
(0.14M NaCl, 2.7mM KC1, 10mM NaHPO 4 and 1.8mM KH2PO4, lg/L BSA, pH
adjusted to 7.4). All experiments were performed in PBS/BSA.
Both rich medium and synthetic mediums were used for yeast cultures. Rich
medium YPD was prepared with 10g/L yeast extract, 20g/L peptone and 20g/L dextrose.
Synthetic medium SD-CAA contained 20g/Lglucose, 7g/L yeast nitrogen base, 5.4g/L
Na2HPO4, 7.4g/L NaH 2PO4 and 5g/L casamino acid (-ura, -trp, DIFCO, Franklin Lakes,
NJ). SG-CAA was prepared in the same way as SD-CAA, except glucose was replaced
with 20g/L of galactose. SD-SCAA and SG-SCAA (-ura, -trp, -leu) were also prepared
similarly, except 2x SCAA synthetic amino acid instead of casamino acid was used
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(Shusta, et al., 1998). SD-SCAA agar plates with different amino acid supplements were
prepared similarly as the media listed above, except with additional 17g/L of agar
(DIFCO) and 182g/L of sorbitol.
4.2.3 Growth and Induction
Yeasts containing single display plasmid (pCT302, pCT4M2.5, pCT4M3.6,
pCT4M3.7 or pCT201-DI.3) were grown in SD-CAA at 300C (in a 250rpm shaker) for
24 hr. To induce the display of scFv, cells from the SD-CAA cultures were collected to
inoculate 5 ml of SG-CAA to a starting OD600 of about 1. These cultures were grown at
200C for 20 to 22hr. Yeasts containing one display plasmid and an extra LEU2 plasmid
(pRS315) were grown and induced identically, except the media used for growth and
induction were SD-SCAA and SG-SCAA (-ura, -trp, -leu) respectively. Non-displaying
cells (nonbinders) were prepared by growing yeasts containing only LEU2 plasmid
(pRS315) in SD-SCAA (-ura, -leu) media at 300C for 24 hr.
4.2.4 Fluorescence Labeling and Measurements
About 2 x 106 yeast cells display anti-fluorescein scFv were incubated with 80nM
fluorescein-biotin (FL-B) at 250C for 30min (time for equilibrium binding). There was
about 50-fold molar excess of FL-B over antibody, assuming 105 scFv per cell. After the
primary label, cells were washed in cold PBS/BSA (40 C) and then incubated on ice with
streptavidin-phycoerythrin (1:100 dilution) for 30min. Shorter secondary labeling time
(about 7 min) was used for labeling wild-type 4-4-20 displaying cells to prevent
extensive dissociation of primary label. Cells, with secondary label, were washed and
then suspended in cold PBS/BSA. The mean fluorescence of the cells was measured by
Coulter® Epic® XLTM flow cytometer.
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4.2.5 Binder Identification from Magnetic Bead Capture
Experiments with different initial ratios of 4-4-20 displaying cells (binder) to
nonbinders were performed. At least 1000 4-4-20 cells were used to avoid stochastic
effects of small numbers (small number of binders recovered from the magnetic beads)
on experimental results. The initial concentrations of nonbinders were either
lxlO7cells/ml or lxlO8cells/ml, depending on the binder to nonbinder ratio required. In
each experiment, 4-4-20-displaying cells and excess of nonbinders were mixed in I ml
PBS/BSA, and incubated with 80nM of FL-B (about 50-fold molar excess) at 21°C for 1
hr on a rotator (20rpm). Excess ligand was washed away in cold PBS/BSA (40C), and
then cells with FL-B bound were mixed with streptavidin-labeled magnetic bead at a ratio
of 10 beads to 1 cell displaying scFv (bead to binder ratio was optimal at a ratio about
10:1 and at least 108 beads/ml was required to prevent bead loss during procedural
handling, data not shown). Microcentrifuge tube containing magnetic beads and cells was
simply end-over-end turned at 40 C for 2min. Capture was performed at 40C to prevent the
dissociation of bound ligand. A magnet was then applied to select out the beads, and the
supernatants were removed. The magnetic beads with attached cells were cultured in 2ml
YPD media at 300C (in a 250rpm shaker) for about 3 hours (more than one doubling
time) to separate the captured cells from the beads. Dilutions of starting culture,
supernatant collected and culture grown from the beads were plated on SD-SCAA (-ura, -
leu, 4-4-20 + NB) and SD-SCAA (-trp, -ura, -leu, 4-4-20) agar plates to determine the
enrichment ratio and supernatant loss percentage.
Selection with applied shear force was performed to isolate binders from excess
of nonbinders. About 960 4-4-20-displaying cells and 1.07 x 108 non-binders were
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mixed, incubated with 80nM FL-B at 21°C for lhr on a rotator (20rpm), washed and then
captured by magnetic beads at 4C, as previously described. After the first capture,
magnetic beads with attached cells were washed, vortexed for about 15sec and
resuspended in room temperature PBS/BSA. The magnet was applied and the supernatant
was removed. The supernatant collected from the wash was incubated with 80nM FL-B
at 21C for lhr on a rotator again and then captured by magnetic beads at 40 C without
additional vortexing (simple end-over-end turning). The magnetic beads from the first
and second captures were pooled together and grown in 2ml YPD media at 300C for
about 3 hours to isolate cells from the cell/bead complexes. Dilutions of starting culture,
supernatant collected and culture grown from the beads were then plated on SD-SCAA(-
ura, -leu, 4-4-20 + NB) and SD-SCAA(-trp, -ura, -leu, 4-4-20) agar plates. The same
procedure (selection with shear) was performed to enrich 1600 D1.3 displaying cells
from 1.68 x 108 nonbinders, except cells were labeled with 80nM of biotinylated HEL,
instead of FL-B, at 21 °C.
4.2.6 Dissociation Kinetics by Fluorescent Measurement and Magnetic Bead
2 x 106 anti-fluorescein displaying cells were incubated with 80nM FL-B at 2 1°C
for 1 hr, washed with cold PBS/BSA, and then incubated with 560nM of 5-
aminofluorescein, a competitor (about 350-fold molar excess) at 2 1C for different length
of time. At different points in the competition phase, cells were washed with cold
PBS/BSA and labeled with streptavidin-phycoerythrin at 40 C for 30min. After secondary
labels, the cells were washed and their mean fluorescence was detected by a flow
cytometer. The decrease of mean fluorescence (F) as a function of time was fitted with an
exponential decay function (F=Foe-kt+F , where F is the initial mean fluorescence of
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labeled cells and Fo is the background fluorescence of unlabeled cells) to determine the
dissociation rate constant (k) of polypeptide/ligand complex. Meanwhile, magnetic bead
capture was also used to determine the dissociation kinetics. The procedures were similar
to those by mean fluorescence measurement. Instead, 3 x 106 anti-fluorescein displaying
cells were used, and instead of labeling with streptavidin-phycoerythrin, cells at different
points of competition phase were captured by 108 magnetic beads at 4°C. A magnet was
applied to isolate the magnetic beads and the supernatant was removed. The optical
density (ODo00) of the supernatant was then measured to determine the amount of cells
captured by magnetic beads. The decrease in binder amount (B) as a function of time was
fitted with an exponential decay function (B=Boe'Kt+Bo,, where Bo is the initial amount
of binder and Boo is the amount captured due to non-specific binding) to determine the
dissociation rate constant (K) of bead/cell complex.
4.2.7 Kinetic Screening by Magnetic Bead Capture
4M3.6-displaying cells were transformed with a standard pRS315 CEN shuttle
vector providing the Leu marker. This additional plasmid did not affect cell growth or
surface expression but allowed for the differentiation of cells on selective media plate.
About 5.4 x 103 of 4M3.6 cells and 8.7 x 106 of 4M2.5 cells were mixed, saturated with
80nM FL-B at 21°C for I hr on a rotator (20rpm), washed and incubated with 5-
aminofluorescein at 2 1C on a rotator (20rpm) for different lengths of competition times.
Then, at different points of competition phase, cells were washed with minimal shear
force and then captured by the magnetic beads at 4°C. The magnetic beads with attached
cells were cultured in 2ml YPD media at 300C (in a 250rpm shaker) for about 3 hr.
Dilutions of the starting culture, supernatant collected and cultures grown from magnetic
102
beads, were plated on SD-SCAA (-ura, -trp, -leu, 4M3.6) and SD-SCAA (-ura,-trp,
4M2.5 + 4M3.6) media.
Selection with applied shear force was carried out to kinetically screen for
improved mutants. About 600 4M3.6 cells and 5.7 x 107 4M2.5 cells were mixed and
screened kinetically as described above with 90min of competition time. However, after
the first capture, isolated magnetic beads with cells bound were vortexed in PBS/BSA
solution for about 10sec. Then, supernatant was removed and those vortexed magnetic
beads were cultured in YPD media at 300C for about 3 hr. Dilutions of cultures were
plated as described above.
4.3 Results
4.3.1 Model System Validation
The model antibody used for most of these studies is the anti-fluorescein antibody
4-4-20 and higher affinity mutants, which were described earlier (Boder, et al., 2000).
Four different anti-fluorescein scFv fragments with varying dissociation rate constants,
namely 4-4-20 (wild type), 4M2.5, 4M3.6, and 4M3.7, were displayed as a monolayer on
the surface of Saccharomyces cerevisiae cells.
Flow cytometry quantitatively discriminates cell surface ligand density variations
via fluorescence intensity differences. The capability of magnetic bead capture to
discriminate cell surface ligand density differences was tested. Yeast cells displaying
anti-fluorescein scFvs were labeled with different surface densities of fluorescein biotin
(as described in Materials and Methods), and then captured with streptavidin-coated
magnetic beads. Figure 4.1 shows that the cell capture probability (capture fraction) by
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Figure 4.1 Capture Probability of anti-Fluorescein scFv Displaying Cells by
Magnetic Beads Increases with Increasing Surface Ligand Density. Cells labeled with
varying levels of fluorescein-biotin ligand were captured by streptavidin-labeled
magnetic beads. Cells were also labeled with streptavidin-phycoerythrin and their mean
fluorescence is determined by flow cytometer. Capture probabilities of cells displaying
three different scFv mutants are plotted as a function of mean fluorescence of the
mutants. The line represents an exponential least-square fit of all three data sets, simply
as an empirical correlation without a theoretical basis. * = cells displaying scFv 4M2.5
(koff =6.9 x 10 2min- at 21°C), · = cells displaying scFv 4M3.6 (kotf =8.9 x 10-3min'l at
21°C), and = cells displaying scFv 4M3.7(koff =4.0 x 10-3min-' at 21°C). Error bars
represent mean standard deviations of three replicates.
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magnetic beads increases with increasing surface ligand density and levels off at high
surface ligand density. Cells with higher surface ligand density have a monotonically
higher probability of being captured by the magnetic beads. Furthermore, the correlation
between ligand density and bead capture is surprisingly quantitative given the potential
variability in multivalency, shear, and mixing conditions. This result indicates that
magnetic beads are able to preferentially capture cells with higher ligand density in a
fashion analogous to flow cytometric sorting, and provides the fundamental basis for
using magnetic beads to perform quantitative screening.
Two important indicators were considered to gauge the success of a screening
experiment: the single-pass enrichment ratio (defined as the ratio of the fraction
consisting of the desired subpopulation before and after screening) and the percentage
loss of cells displaying the binding protein of interest ("binders"). Ideally, the single-pass
enrichment ratio should be as close to the theoretical maximum enrichment ratio as
possible (high purity), whereas the percentage loss should be as low as possible (high
yield). However, a tradeoff between yield and purity is generally to be expected, as for
all separations processes.
Direct plating of the cells on selective media was validated as a measure of screen
success by comparison with mean fluorescence measurements by flow cytometry.
Approximately equal numbers of 4-4-20-displaying cells (yeast strain EBY100
transformed with pCT302) and non-displaying cells (yeast strain EBY100 transformed
with pRS315) were mixed, incubated with FL-B, washed and then captured with
magnetic beads. Separately, those cultures were also labeled with streptavidin-
phycoerythrin, and immunofluorescent labeling was measured in a flow cytometer. The
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percentage loss of binders and the enrichment ratio were then determined by each
method. Table 4.1 shows the initial proportion of binders to non-binders, the supernatant
loss percentage and the enrichment ratio from direct plating and flow cytometric analysis.
Note that the initial proportion of binder to non-binder calculated from the direct plating
is somewhat different from flow cytometric analysis. A certain measurable proportion
(about 20-50%) of cells carrying plasmid pCT302 (4-4-20) do not display scFv on the
surface (likely due to retention in the secretory pathway) (Robinson and Wittrup, 1995),
and are characterized by a negative peak in the histogram. However, these cells are still
capable of synthesizing trytophan due to the presence of the TRPI gene on the pCT302
plasmid, and survive in SD-SCAA (-trp,-ura) media. This accounts for the higher initial
binder proportion measured by the plating method. After correcting the display fraction
in 4-4-20-displaying cells, Table 4.1 shows that the supernatant loss percentage and
enrichment ratio determined from the direct plating agree well with those from the flow
cytometric analysis. Therefore, direct plating was used to determine the supernatant loss
percentages and enrichment ratios in subsequent experiments where the percentage of
binders is too small to reliably measure by flow cytometry.
4.3.2 Isolation of binders from nonbinders
Identification of lead molecules from large diverse repertoires requires selection
of rare binding events from a large excess of nonfunctional clones. The proficiency of
magnetic bead separation to isolate binders from excess nonbinders was examined.
Experiments with different ratios of nonbinders to binders were performed to determine
their respective enrichment ratio and supernatant loss percentage. Minimal shear force
was applied in the washing step to avoid separating captured cells from the magnetic
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Table 4.1 Agreement of Direct Plating and Fow Cytometer Results for Displayed
Fraction. Supernatant loss percentage and single-pass enrichment ratio of 4-4-20-
displaying cells from excess of non-displaying cells (EBY100::pRS315) are determined
from direct plating and flow cytometry.
-Trp plates +Trp plates
(Method) (4-4-20) (4-4-20 + NB) Proportion
Initial Population
(Plating) 4.36 + 0.07 x 106 1.13 + 0.08 x 107 39 + 4 %b
(Cytometer) 18.9 ± 0.9%
Corrected for the display population of 4-4-20
Maximum theoretical
Methods Supernatant loss % Enrichment ratio enrichment ratio
Plating 4.4 + 0.4% 5.0 ± 0.7 5.3
OD + Cytometry 7.49 + 0.16% 4.02 ± 0.11
a NB- Non-Binder, EBYL00::pRS315
b Average and standard deviation of three replicates
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beads (i.e. manual end-over-end turning of a microcentrifuge tube for 2 minutes). As
shown in Table 4.1, under a starting proportion of about 5 nonbinders to 1 binder, the
enrichment ratio is about 4 to 5-fold and the supernatant loss percentage is about 4 to 7%.
Figure 4.2 shows the single-pass enrichment ratio and supernatant loss percentage of
binders at binders to non-binder ratios of 1:14 to 1:60000. The initial total cell
concentration (binders + nonbinders) was about 107 cells/ml for all but one ratios, at
1:60000, the initial total concentration was about 108 cells/mi. This tenfold higher
concentration of initial non-binder at 1:60000 leads to a somewhat higher extent of steric
effect and non-specific binding to the magnetic beads, resulting in a lower single-pass
enrichment ratio.
To enhance the single-pass enrichment ratio, shear force was applied in the
washing step to lower non-specific binding of cells to the magnetic beads (refer to
Materials and Methods section for detailed procedure.) Table 4.2 shows that with a
starting ratio of about 1 binder in 1 x 105 nonbinders, the single-pass enrichment ratio is
9400 fold and the supernatant loss percentage is 85%. The results indicate that shear
force increases the single-pass enrichment ratio, at the cost of an increase in the
supernatant loss percentage, as shear force strips specific binders from beads. As
expected, higher enrichment ratio is attained at the cost of a decreased yield of binders.
Having demonstrated that the magnetic bead capture protocol is capable of isolating
binders in an antibody/hapten (4-4-20/fluorescein) recognition system, an antibody
/protein antigen recognition system was tested to generalize this protocol. The
antibody/protein system used was D1.3, an anti-hen egg lysozyme (HEL) antibody, and
HEL. The scFv fragment of D1.3 was displayed on the surface of yeast cells. The Dl.3
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Figure 4.2 Single-Pass Enrichment Ratio (A) and Supernatant Loss Percentage (B)
of Binders (4-4-20-Displaying Cells) from Non-Binders (NB, Non-Displaying Cells)
at Different Initial Ratios. The single-pass enrichment ratio and supernatant loss
percentage are calculated from the direct plating of the starting culture, supernatant and
the culture captured on bead. Minimal shear force is applied to remove captured cells on
the magnetic beads (i.e. end-over-end mixing). Individual data set (each ratio of binder to
non-binder) is performed on separate days and with freshly prepared cells. The initial
total cell concentration is 10 7 cells/ml for all experiments except at 1:60000, where total
cell concentration is 108 cells/mi. Error bars represent mean standard deviation of three
replicates.
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Table 4.2 Vigorous Shear Force Increases the Single-Pass Enrichment Ratio of
Binder from Non-Binder. Supernatant loss percentage and single-pass enrichment ratio
of 4-4-20-displaying cells from excess of non-displaying cells (EBY1OO::pRS315) with
shear force applied in the washing step.
-Trp plates +Trp plates Enrichment
(Method) (4-4-20) (4-4-20 + NBa) Proportion Loss (max. theoretical)
Start
960 + 140 1.07 +0.02 x 108 9.0 + 1. 4 x104%b
Supernatant
810+60 1.05+0.09x 108 7.7 0.8x10-4% 85 6%
Recovered
from bead
120 + 40 1500 + 700 8.4 + 1.5% 9400 + 1800 fold
(110000-fold)
a NB- Non-Binder, EBY100::pRS315
b Average and standard deviation of three replicates
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procedure was similar to the procedure of isolating 4-4-20-displaying cells under shear
condition, except biotinylated HEL was used as linker. Table 4.3 shows that the single-
pass enrichment ratio of DI.3-displaying cells is about 1200 fold, and the supernatant
loss percentage is about 80%. Variability was somewhat higher for this antibody/antigen
system in three independent replicate experiments, for unknown reasons. These data
show that magnetic bead isolation is generalizable to antibody/protein antigen systems.
4.3.3 Affinity Maturation
In addition to isolating new binding molecules, a common application of library
screening is affinity maturation of a lead-binding molecule. The ability of magnetic beads
to isolate improved library mutants from an excess of lower-affinity mutants was
examined. Improved binding mutants within a library may be isolated by selectively
labeling in an equilibrium binding screen or by a kinetic screen for slowed dissociation
(Boder and Wittrup, 1998). Magnetic bead screening utilizes analogous equilibrium and
kinetic screens as in flow cytometric screening. In an equilibrium screen, cells displaying
polypeptides are incubated at a concentration of labeled ligand below the equilibrium
dissociation constant of the wild-type polypeptide/ligand complex. Cells displaying high-
affinity polypeptides will be preferentially labeled compared to those cells displaying
low-affinity polypeptides. As shown in Figure 4.1, cells labeled with higher surface
ligand density will be preferentially captured on the magnetic bead. Concentration of the
labeled ligand will likely determine the range of enrichment achieved in an equilibrium
screen. In a kinetic screen, an excess of unlabeled ligand is added to cells displaying
polypeptides that are first labeled to saturation with labeled ligand. The decrease in cell-
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Table 4.3 Enrichment of Binder from Non-Binders using Protein Antigen
(Lysozyme). Supernatant loss percentage and single-pass enrichment ratio of DI.3-
displaying cells from non-displaying cells (EBY100::pRS315) with shear forces applied
in the washing step.
-Trp plates +Trp plates Enrichment
(Method) (D1.3) (DI.3 + NB a) Proportion Loss (max. theoretical)
Start
1600 400 1.68 + 0.11 x 108 9 .5 + 1.7x 10-4%b
Supernatant
1260 130 1.6 + 0.2 x 108 7.9+ l.lx 10-4% 80+ 20%
Recovered
from bead
310 + 160 1.4 + 2.1 x 105 1.2 + 1.6% 1200 + 1400-fold
(110000-fold)
a NB- Non-Binder, EBY100::pRS315
b Average and standard deviation of three replicates
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bound labeled ligand is followed with time. Mutants with slower polypeptide/ligand
dissociation constant will preferentially have higher labeled ligand density on their
surfaces, resulting in a higher probability of capture by magnetic beads. In a kinetic
screen, the duration of competition time will determine the range of affinity improvement
likely to be selected from the library.
Dissociation kinetics of 4M2.5, 4M3.6 and 4M3.7 displaying cells were tracked
by mean fluorescence measurement and magnetic bead capture. The dissociation of
bound ligands from cell surfaces directly resulted in a decrease of mean fluorescence of
the cells. The monovalent polypeptide/ligand dissociation rate constants could be
determined by fitting the decrease in mean fluorescence to an exponential decay.
Meanwhile, cells with decreasing surface-bound ligands also resulted in a decrease of the
amount of binders captured by magnetic beads. The multivalent cell/bead dissociation
rate constants could be determined by monitoring the decreasing capture probability.
Figure 4.3 shows the dissociation kinetics of three different scFv displaying cells: 4M2.5,
4M3.6 and 4M3.7 determined both by mean fluorescence measurement and magnetic
bead capture at 2 1°C. (The data presented in Figure 4.3 were those used to construct the
relationship shown in Figure 4.1.) The dissociation rate constants determined by mean
fluorescence measurement at 21°C were 6.9 x 10-2min- l, 8.9 x 10-3min- l, and 4.0 x 10-
3min-' for 4M2.5, 4M3.6 and 4M3.7 respectively. Meanwhile, the dissociation rate
constants determined by magnetic bead capture at 21°C were 4.9 x 10-2min- ', 2.9 x
103min-l, and 2.1 x 10-3min- ' for 4M2.5, 4M3.6 and 4M3.7 respectively. The dissociation
kinetics of antibody/hapten and cell/bead complexes tracked by respective methods were
surprisingly similar. The characteristic dissociation rate constants determined by bead
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Figure 4.3 Quantitative Dissociation Rates Tracked by Magnetic Bead Capture.
Dissociation rates of ligand from cell surfaces are determined for three anti-fluorescein
scFv displaying cells: (A) 4M2.5, (B) 4M3.6 and (C) 4M3.7 by magnetic bead capture
and mean fluorescence measurement. · = dissociation rate by magnetic bead capture. A
= dissociation rate by mean fluorescence measurement. Data are fit to an exponential
decay with nonlinear least-square regression (solid line for mean fluorescence
measurement, dashed line for magnetic bead capture). Mean fluorescence is normalized
by initial fluorescence, and amount of cell capture is normalized by the initial amount of
binder. Error bars represent mean standard deviations of three replicates.
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capture were lower than the dissociation rate constants from the fluorescence
measurement. Bead/cell complex formation involves multivalent interactions of antibody
and hapten on the beads and cell surfaces, and this avidity effect would be expected to
contribute to the observed slower dissociation rate. These results indicate that magnetic
bead capture is capable of tracking dissociation rates in nearly as quantitative a fashion as
mean fluorescence measurement.
A validation experiment for a magnetic bead kinetic screening protocol was
performed to enrich 4M3.6-displaying cell (high affinity mutant) from an excess of
4M2.5-displaying cells (7.7-fold slower in polypeptide/ligand dissociation rate). The
initial ratio of improved mutant (4M3.6) to "wild-type" (4M2.5) was 1:1600 (refer to
Materials and Methods for procedure). During the experiment, cells were washed with
minimal shear force. Figure 4.4 shows the enrichment ratio and supernatant loss
percentage of 4M3.6 as a function of competition time. As in kinetic screening by flow
cytometry, the enrichment ratio increases initially with competition time, peaks at an
optimal competition time, and eventually decays back to about 1 (no enrichment) as
labeling reaches background (Figure 4.4A). Meanwhile, the loss of 4M3.6 increases with
increasing times (Figure 4.4B), as the labeled ligand on 4M3.6 displaying cells continue
to dissociate. Thus, magnetic bead separation can kinetically screen for slower
dissociation mutants, as with flow cytometry.
The effect of applied shear force on the enrichment ratio and supernatant loss
percentage of a kinetic screen was determined. The initial ratio of improved mutants to
wild type was 1:106. After the first capture, the magnetic beads with cells attached were
vortexed in PBS/BSA (refer to Materials and Methods for detail procedure). Table 4.4
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Figure 4.4 Kinetic Screen for Slower Dissociation Rate Mutants. Single-pass
enrichment ratio (A) and supernatant loss percentage (B) of 4M3.6-displaying cells from
excess of 4M2.5 displaying cells as a function of the competition time. Using magnetic
bead, kinetic screen is performed to enrich 4M3.6-displaying cells (koff =8.9 x 10 3min- at
21°C) from excess of 4M2.5-displaying cells (koff =6.9 x 10'2min - ' at 21°C). Initially, the
ratio of 4M3.6-displaying cells to 4M2.5-displaying cells is 1:1600. 5-aminofluorescein
is used as a competitor and the competition is performed at room temperature (21 ° C).
Minimal shear force is applied during the bead washing step. Error bars represent mean
standard deviation of three replicates.
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Table 4.4 Shear Enhancement of Enrichment Ratio in the Kinetic Screen.
Supernatant loss percentage and single-pass enrichment ratio of 4M3.6-displaying cells
from excess of 4M2.5-displaying cells under kinetic screen without and with additional
shear force applied in washing step.
-Leu plates +Leu plates Enrichment a
(Method) (4M3.6) (4M3.6 + 4M2.5) Proportion Loss (max. theoretical)
Start
600 + 170 5.7 +0.7 x 107 1.04 + 0.12x10-3% 
Without Shear
Supernatant
180 + 30 5.1 + 0.3 x 107 26 +10%
Recovered
from bead
590 + 70 7.5 + 0.3 x 105 8.0 + 1.0 x 10-2% 70 + 20-fold
(96000-fold)
With Shear
Supernatant
410+40 5.11 +0.1 x 107 75+24%
Recovered
from bead
157 + 15 2.81 + 0.19 x 104 0.56 0.07% 600 + 200-fold
(96000-fold)
a90min of competition time
b Average and standard deviation of three replicates
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shows the enrichment ratio and supernatant loss percentages for the kinetic screen with
and without additional shear applied. With additional shear, there is about a 10-fold
increase in single-pass enrichment ratio and about 3-fold increase in supernatant loss
percentage. Table 4.4 shows that shear reduces the amount of cells captured by beads,
with more significant effect on low-affinity binders. Low-affinity binders have relative
lower surface ligand density than high-affinity binders after the competition, rendering
the low-affinity binders more easily removed by shear. Thus, shear can increase single-
pass enrichment ratio in a kinetic screen by magnetic beads, at the expense of higher
percentage loss of improved mutants. Therefore magnetic beads are capable of
quantitatively screening for both novel binders and improved mutants.
4.4 Discussion
Magnetic bead capture has been shown to quantitatively discriminate varying
surface ligand density as in flow cytometry, with magnetic bead cell capture probability
correlated strongly with cell surface ligand density. Magnetic bead capture is able to
isolate binders from an excess of nonbinders in both antibody/hapten and
antibody/protein systems. Particularly, with an initial ratio of a one antibody-displaying
cell (binder) in 1.1 x 105 non-displaying cells (a frequency of binders typical for a small
library), a single-pass enrichment ratio of 9400 ± 1800 fold with a 85 ± 6% binders loss
are achieved from screening an antibody/hapten library. In addition, magnetic bead
capture is capable of tracking dissociation kinetics of ligand/cell complexes and
performing a quantitative kinetic screen for improved mutants with slower dissociation
rate. With the presence of 7.7-fold higher affinity clones at 1: 95,000 in the initial library,
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the magnetic bead method is able to enrich the improved mutant 600 + 200-fold, at the
expense of 75 + 24% probability of loss.
The sticking probability of cells mediated by specific cell surface interactions
such as antibody/antigen under uniform shear force has been examined previously both
theoretically and experimentally (Bell, 1978; Bell, 1981; Capo, et al., 1982; Long, et al.,
1999). The models developed are generally based on two-body collision (formation of
doublets), whereas in the experiments reported here, a cluster of (more than two) beads
and cells in complex is formed by multiple collisions. These models, however, can still
give some insight into the dependence of surface ligand density, intrinsic dissociation rate
and shear effect on the formation and breakage of bead/cell complexes. Bell employed
the frequency and duration of cell-cell collision and the number of bonds needed and
required to hold the cells together to determine the sticking probability (Bell, 1981).
Long et al. extended Bell's model to formulate the sticking probability from a set of
binding kinetics equations of receptors and ligands (Long, et al., 1999). Both models and
experimental results (Capo, et al., 1982) demonstrate that the two-body collision capture
frequency (doublet formation rate) is linearly proportional to the cell surface ligand
density at low surface ligand density. This dependence provides the fundamental basis for
using magnetic beads to perform quantitative screening and agrees with our experimental
results that higher surface ligand density leads to higher capture probability. In addition,
once the bead/cell complexes are formed, external force (shear) on the bonds tends to
accelerate their dissociation. Bell formulated the shear effect as an exponential
dependence on the apparent reverse rate constant (k") as follows (Bell, 1978)
k = k exp( f )T (1)
kTN
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where k is the zero-force (intrinsic) reverse rate constant, y is the bond interaction
parameter, F is the force, N is the number of bonds, k is the Boltzmann constant and T is
the absolute temperature. Equation I shows that increasing the shear force or having
fewer bonds will increase the apparent reverse rate constant. During kinetic screening, the
dissociation of ligands from cells displaying lower affinity receptors will be faster. Cell
with lower surface density with be under high force per bond rendering them easier to
separate from the bead/cell complex. This is shown by the shear enhancement of
enrichment ratio in both binder identification and kinetic screening cases, as the shear
force preferentially removes the lower affinity binder (binder with lower surface density).
The enrichment ratios obtained from magnetic bead screening indicate that
magnetic bead capture is able to quantitatively screen for improved mutants, as with flow
cytometric analysis. It is very difficult to exactly compare the enrichment ratios obtained
here with those from flow cytometric analysis, because of the different experimental
conditions, but a comparison should provide some insight into the potential for the
magnetic screening method. Francisco et al. were able to achieve an enrichment ratio of
about 300 fold each round in purifying the binders from 105-fold excess background
bacteria to almost homogeneous in two rounds (Francisco, et al., 1993). Enrichment
factors of 2,000-10,000 fold per round may be achieved under optimal conditions
(Georgiou, et al., 1997). These enrichment factors are comparable to those reported here.
Using kinetic screening by flow cytometry, VanAntwerp and Wittrup were able to enrich
a two-fold higher affinity mutant 125 ± 65 fold with the presence of high-affinity mutant
at a starting ratio 1:1000 (VanAntwerp and Wittrup, 2000). The magnetic bead method is
able to achieve 70 to 600-fold enrichment factors in kinetic screening. Overall, based on
120
the single-pass enrichment ratios obtained, magnetic bead screening of cell-based
polypeptide libraries appears to be approximately equivalent to flow cytometry.
Compared to flow cytometric analysis, magnetic bead screening method has both
advantages and disadvantages. Magnetic bead screening is cheap, simple, fast, and
convenient. It also has higher throughput than flow cytometric analysis, facilitating easy
scale-up of library size to increase the number of clones of interest if needed. Therefore,
larger libraries (> 108 clones) can be sorted as readily and quickly as smaller library (106 -
107 clones). However, a potentially significant disadvantage of magnetic bead screening
is that it cannot discriminate an expression mutant (higher expression level) from true
functional mutant (higher binding affinity). Due to the avidity effect from magnetic bead
capture, a highly expressed low-affinity mutant may be captured at the same probability
as a poorly expressed high-affinity mutant. By contrast, flow cytometric analysis can
explicitly account for variation in the expression level with epitope normalization (two-
color FACS). The fluorescence intensity of a second probe, which is used to specifically
label a constant part of the displayed protein and quantify the expression level, is used to
normalize the binding signal, facilitating the selection of functional traits independent of
expression level (Boder and Wittrup, 1997). In addition, magnetic bead screening is not
able to provide real-time quantitative multi-parameter statistical analysis of every library
member as in flow cytometry. Although varying amounts of magnetic beads can
potentially alter the amount of cells captured, the number of cells to be collected cannot
be easily set as for flow cytometry. The gate setting of flow cytometric analysis can be
readily modified to collect any desired fraction of the library. With a more sophisticated
approach, such fine discrimination and fractionation of immunomagnetically labeled cells
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may be achievable with colloidal or molecular magnetic labels in the near future
(Chalmers, et al., 1998).
Magnetic beads have been utilized extensively in screening phage display
libraries. For affinity maturation of D1.3 using phage display, 5 rounds of magnetic bead
screening were used to enrich a mutant 106 fold by kinetic screening (Hawkins, et al.,
1993). From our kinetic screening results, initial single-pass enrichment ratio of 600 ±
200 fold is achieved. Therefore, we would predict that three to four rounds of magnetic
bead screening should be sufficient to purify an improved mutant from a yeast-surface
displayed library. As an approximate comparison, magnetic bead screening of yeast-
surfaced displayed library compares well with phage display. In addition, adsorptive
losses of rare clones are less significant in a yeast library, because phage particles, being
much smaller than yeast cells, have higher tendencies to stick to glassware or beads.
Also, only three to five copies of polypeptides are displayed on phage, so molecular
randomness or stochastic effects inherent in the small number of binding reactions can
lead to loss of rare clones. High copies of polypeptides (104-105 (Boder and Wittrup,
1997)), however, are displayed on the yeast surface, essentially eliminating random
fluctuations by extensive averaging.
Earlier efforts at directed evolution with multivalently displayed phage were
found to lead to extensive avidity effects that obscured the desired monovalent binding
properties being engineered (e.g., only 2/11 selected antibodies exhibit higher affinity
against phOx antigen (Griffiths, et al., 1994)). Such artifacts are not a substantial issue
for the approach described here, because the intrinsic competition occurs relative to a
monovalent interaction with soluble biotinylated antigen, followed by a rapid capture step
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that depends only on surface ligand density. The likely multivalent interactions between
cells and beads serve only to define the bead capture probability relationship represented
in Figure 4.1, whereas the surface ligand density is related directly to the monovalent
binding equilibria and kinetics at the cell surface. Therefore, the capture probability is
governed by well-defined monovalent binding interactions rather than the ill-defined (but
empirically reproducible) cell-bead complex formation kinetics.
Magnetic bead capture has been shown to be a high-through quantitative
screening tool for cell-based libraries. Magnetic bead screening can potentially be
employed to screen cell-based naive antibody libraries of >109 clones to identify
antibodies against antigens of interest. As described here, magnetic bead screening
currently utilizes soluble biotinylated antigen. One obstacle to use of a cell-based
polypeptide library is the incapability of screening or selecting mutant cells against a
membrane-bound antigen. Magnetic separation holds a conceivable solution to this
problem. The understanding of the formation and breakage of bead/cell complexes should
provide further insight into the cell/cell interactions, such as avidity effect, external shear
effect, steric effect, non-specific binding and so on, and eventually could lead to
development of screening protocols for cell-based polypeptide library against a
membrane-bound antigen.
4.5 Conclusion
Currently, flow cytometric analysis has been employed extensively to
quantitatively screen cell-based library for novel binders and improved mutants. Due to
the limited availability of flow cytometers in many laboratories, magnetic bead screening
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has been developed as an alternative quantitative screening tool for cell-based libraries.
Specifically, the library is first equilibrated with biotinylated ligand, and then binders are
isolated with streptavidin-coated magnetic beads. Results indicate that close to 10000-
fold single-pass enrichment ratio are possible in screening for novel binder, and 600-fold
single-pass enrichment ratio is achievable in a kinetic screening for a 7.7-fold higher
affinity mutants. Magnetic bead separation is fast, simple, and convenient. The described
methods are similar to procedures in common use for phage display, and should lower the
barriers to entry for use of cell surface display libraries.
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Appendix
Amino acid sequences of anti-HAAH scFv directly isolated from the non-immune
library. CDRs of the antibody are highlighted in yellow.
Clone 4-6
QVQLVQSEGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISY
DGSNKYYADSVKGRFTISRDNS KNTLYLQMNSLRAEDTAVYYCARDYYDFWSG
SSPSYYYYGMDVWGQGTTVTVSSGSASAPTRNSRIRWRWQRRWWFRRRRAAGI
L
Clone 6-8
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTY
YRTKWYNEYAASVKGRATINPDTSKNQFSLQLNSVTPEDTAVYYCATDPKGVTT
QYWGQGTLVTVSSGSASASTGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTP
GQRVTISCSGSTSNIGRNYVYWYQRLPGTAPKLLIYRNNQRPSGAPARFSGSKSG
TSTSLAISGLRSEDEAEYFCAAWDDSLSGWVFGGGTQLTVL
Clone 6-12
QVQLQQSGPGLVKPSQTLSLTCGISGDSVSSNSAAWNWIRQSPSRGLEWLGRTY
YRSRWYNDYAASVKSRITVNADTSKNQFSLQLNSVTPEDTAVYYCARSVRYSSG
WGFDYWGQGTLVTVSSGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTPGQRI
TISCSGSSSNIGNNYVYWYQQFPGTAPKLLVYRNNQRPSGVPDRFSGSKSGTSAS
LAISGLRSEDEADYYCAAWDDSLSGRWVFGGGTKLTVL
Clone 6-13
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSRNSAAWNLIRQSPSRGLEWLGRTYY
RSKWYTDYAVSVKSRITINPDTSKNQFSLRLNSVTPEDTAVYYCARSGGGHAAG
KFDSWGRGTLVTVSSGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTPGQRVTI
PCSGSSSNIGSKYVYWYQHLPGTAPKLLIYRNNQRPSGVPDRFSGS KSGTSASLAI
SGLRSEDEADYYCAAWDDSLSAWVFGGGTKLTVL
Clone 6-14
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSATWNWIRQSPSRGLEWLGRTY
YRSKWYNDYAVSVKSRMTINPDTSKNQFSLQLNSVTPDDRAVYYCARGGRLGG
GMDVWGQGTTVTVSSGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTPGQRV
TISCSGSSSNIASNYVYWYQHLPGTAPKLLIYTNNRRPSGVPDRFSGSKSGTSASL
AISGLRSEDEADYFCAAWDDSLSGWVFGGGTKVTVL
Clone 6-22
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTY
YRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARTGYSSSW
VVNFDYWGQGTLVTVSSGSASAPTGILGSGGGGSGGGGSGGGGSQPVLTQSPSA
SGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGS
KSGTAASLAISGLQSEDEADYYCAAWDDSLRGYVFGTGTKLTVLS
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Clone 6-23
QVQLVQSEGGVVQPGRSLRLSCGVSGFTFSSYAMHWVRQAPGKGLEWVAVISY
DGSKKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRVTTGITRY
FDLWGRGTLVTVSSGILGSGGGGSGGGGSGGGGSQSVLTQPASVSGSPGQSITIS
CTGTNSDIGGYNYVSWYQQHPGKAPKLMIFEVTNRPSGVPDRFSASKSGNTASL
TISGLQADDEADYYCSSYAGSNTPSVFGTGTKLTVL
Clone 6-24
QVQLVESEGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVVSY
DGSQDYYADSVKGRFTISRDNSKNTLYLQMNSLRPEDTGVYYCAKVGRSSNWF
SRYYYYGMDVWGQGTTVTVSSGILGSGGGGSGGGGSGGGGSEIVLTQSPATLSL
SPGERATLSCRASQSVSHYLAWYQQKPGQAPRVLIYDVANRAAGTPARFSGSGS
GTDFTLTISS LEPEDFAVYYCQQRSNWPQTFGPGTKVDIK
Clone 6-25
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSDSAAWNWIRQSPSRGLEWLGRTY
YRSKWYNDYAVSVKSRISINPDTSKNQFSLQLNSVTPEDTAVYYCARAQNNIAV
AGFDYWGLGTLVTVSSGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTPGQRV
TISCSGSSSNIGSNYVYWYQQLPGTAPTLLIYRNNQRPSGVPDRFSGSKSGTSASL
AISGLRSEDEAEYYCAAWDDSLSGLYVFGTGTKVTVLS
Clone 6-26
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRTY
YRSKWYNDYAVSVKGRITINPDTSKNQFSLQLNSVTPEDTAMYYCVRSGGGRV
DPWGQGTLVTVSSGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTPGQRVTISC
SGSRSNIGSNYVYWYQQLPGTAPKLLIYRNHQRPSGVPDRFSASKSGTSASLAISG
LRSEDEADYYCAAWDDSLSGYVFGTGTKLTVL
Clone 6-27
QVQLVESEGGVVQPGRSLRLSCAASGFTFGTYAMHWVRQAPGKGLEWVAVISN
DGGHKYYADSVKGRFTISRDNSKDSMYLQMNSLRAEDTAVYHCAKGRPWYDP
GAEYFQHWGQGTLVTVSSGILGSGGGGSGGGGSGGGGSQSALIQPASVSGSPGQ
WITISCTGTS SDVGGYNYVSWYQQHPGKAPKLLIYDVSDRPSGVSNRFSGSKSGN
TASLTISGLQAEDEADYYCSSYTSSNTVLFGGGTKLTVLS
Clone 6-28
QVQLVQSEGGVVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVAVIS
YDGSNKYYTDSVKGRFTISRDNSKNTLYLQMDSLRPEDTALYYCAREASSGWYI
DSWGQGTLVTVSSASTKGPSGILGSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSP
GERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGT
DFTLTISRLEPEDFAVYYCQQYGSSQVTFGQGTRLEVKS
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Amino acid sequences of anti-HAAH scFv isolated from CDR domain shuffling
mutagenesis. CDRs of the antibody are highlighted in yellow.
Clone C 
PVQLQQSGPGLVKPSQTLSLPCAISGDSVSSNSAAWNWIRQSLSRGLEWLGRTYY
RS KWYNDYAVSVKSRITINPDTS KNQFSLQLNSVTPDDTAIYYCARASDYGDYF
YYFDYWGQGTLVTVSSGSASAPTGILGSGGGGSGGGGSGGGGSQPVLTQSPSAS
GTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGS
KSGTAASLAISGLQSEDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
Clone C2
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWLGRIYY
RSKWYYDYAVSVKSRIAIKPDTS KNQFSLQLNSVTPEDTAVYYCARGAGRSFDL
WGRGTLVTVSSGSASAPTGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTPGQ
RVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTA
AS LAISGLQS EDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
Clone C3
QVQLQQSSPGLVKPSQTLSLTCAVSGDSVSGNSGVWNWIRQSPSRGLEWLGRTY
YYTYKWYIDYAVSVKSRITVNPDTSRNQFSLQLNSVTPEDTAVYYCARVDYTGS
PVWGQGTLVTVSSGSASAPTGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTP
GQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGS KSG
TAASLAISGLQSEDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
Clone C4
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSLSRGLEWLGRTY
YRSKWYNDYAVSVRGRITINADTSKNQFSLQLNSVTPEDTAVYYCARTGYSSSW
VVNFDYWGQGTLVTVSSGSASAPTGILGSGGGGSGGGGSGGGGSQPVLTQSPSA
SGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGS
KSGTAASLAISGLQSEDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
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Sequences of anti-HAAH scFv isolated from heavy chain shuffling mutagenesis.
CDRs of the antibody are highlighted in yellow.
Clone LLml
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSITAAWNWLRQSPSRGLEWLGRTY
HRSKWYYDYAVSVKSRITVNPDTSKNQFSLHLNSVTPEDTAVYYCARGLAARG
GGPSAHAFEIWGQGTMVTVSSASTKGPSGILGSGGGGSGGGGSGGGGSQPVLTQ
SPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDR
FSGSKSGTAASLAISGLQSEDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
Clone LLm3
QVQLQQSGPGLVKPSQTLSLTCVISGDSVSNNSAVWNWIRQSLSRGLEWLGRTY
YRSKWYNDYAVSVKSRIIINPDTSKNQFSLQLNSVTPEDTAVYYCARRTGAGVD
YWGQGTLVTVSSGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTPGQRVTISCS
GSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTAASLAISG
LQSEDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
Clone LLm5
QVQLQQSGPGLVKPSQTLSLTCAISGDGVSGNNVIWNWIRQSPSRGLEWLGRTY
YRSKWYYDLLPSVKSRIAINPDTSKSQFSLQLSSVTPEDTAVYYCARTRAVAGNQ
YFDLWGRGTLVTVS SGILGSGGGGSGGGGSGGGGSQPVLTQSPS ASGTPGQRVTI
SCSGSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTAASLA
ISGLQSEDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
Clone LLm6
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSYSAAWNWIRQSLSRGLEWLGRTY
YRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCASLAAAAGT
VDYWGQGTLVTVSSGSASAPTGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGT
PGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKS
GTAASLAISGLQSEDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
Clone LLm8
QVQLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSLSRGLEWLGRTY
YRSKWYNDYALSVKSRININADTSKSQFSLQLDSVTPEDTAVYFCAKDRLLYNY
GSNAMDVWGQGTTVTVSSGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTPG
QRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGT
AAS LA ISGLQSEDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
Clone LLm9
QVQLQQSGPGLVKPSETLSLTCAISGDSVSSNSAAWNWIRQSLSRGLEWLGRTY
YRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCARDTPRYCS
GGSCYKYFDYWGQGTLVTVSSASTKSPSGILGSGGGGSGGGGSGGGGSQPVLTQ
SPSASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDR
FSGS KSGTAASLAISGLQSEDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
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Clone LLm 11
QVQLQQSGPGLVKSSQTLSLTCAISGDSVSSKGAAWNWIRQSPSRGLEWLGRAY
YWSKWYYDYAVSVKSR1TINPDTSKNQFSLQLNSLTPEDTAVFYCARGATSTYY
LPGGLDVWGQGTTVTVSSGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTPGQ
RVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTA
ASLAISGLQSEDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
Clone LLml3
QVQLQQS GAGLVKPSQTLSLTCTISGDSVSADRVAWNWIRQSPLRGLEWLGRIF
YRSKWMVDYAVSVKSRISINPDTSKNQFSLQLNSVTPEDTAMYYCARATTRGYF
DLWGRGTLVTVSSGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTPGQRVTISC
SGSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTAASLAIS
GLQSEDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
Clone LLml4
QVQLQQSGPGLVKPSQTLSLTCVVSGDGVSSNSAAWNWIRQSLSRGLEWLGRT
YYRSKWYNDYAVSMKGRITINPDTSKNQFSLQLDSVTPEDTAVYYCARRSGRTG
GYFDLWGRGTLVAVSSGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTPGQRV
TISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTAASL
AISGLQSEDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
Clone LLml5
QVQLQQSGPGLVKPSQTLSLTCAIPGHSVGSSNAAWNWIRQSPSRGLEWLGRIFY
GSKWYNDYAVSLKSRLTINPDTSKNQFSLQLNSVTPEDTAVYYCARRTGTGIDY
WGQGTLVTVSSGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTPGQRVTISCSG
SSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTAASLAISGL
QSEDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
Clone LLm20
QVQLQQSGPGLVKPSQTLSLTCAISGHSVGSSNAAWNWIRQSPSRGLEWLGRIFY
RS KWYNDYAVSVKTRIS INPDTAKNQFSLHLNSVTAEDTGVYYCARGQQKRLDS
WGQGTLVTVSSGILGSGGGGSGGGGSGGGGSQPVLTQSPSASGTPGQRVTISCSG
SSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTAASLAISGL
QSEDEADYYCAAWDDSLRGYVFGTGTKLTVLSGIL
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Amino acid sequences of anti-HAAH scFv isolated from random mutagenesis of C4
scFv. CDRs of the antibody are highlighted in yellow.
Clone C4-8
RVQLQQLGPGLVKPSQTLSLTCAIFGDSVSSNGAAWSWIRQSLSRGLEWLGRAY
YRSKWYNDYAVSVRGRITINADTSKNQFSLQLNSVTPEDTAVYYCARTGYSSSR
VVSSGYWGQGTLVAVSSGSASAPIGILGSGGGGSGGGGSGGGGSQPVLTQSPSAS
GTPGQRVTIS C S GS S SNIGSNYVYWYQQLPGTAPKLLIYKSNRRPSGVPGRFSGS K
SGTAASLAISGLQSEDEADYYCAAWDDSLRGYVFGTGTKLTVL
Clone C4-18
QVQLQQSGPGLVKPSPTLSLTCAISGDSVSSNSAAWNWVRQSLSRGLEWLGRTY
YRSKWYNGYAVSVRGRITTNADTSRNQFSLQLNSVTPEDTAVYYCARTGYSSS
WVVNSNYWGQGTLVTVSSGSASAPTGILGSGGGGSGGGGSGGGGSQPALTQSPS
ASGTPGQRVTISCSGSSSNIGSNYVYWYQQLPGTAPKLLIYKNNQRPSGVPGRFS
GS KS GTAAS LAIS GLRS KDEADYYCAAWDDSLRGYVFGTGTKLTVL
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